<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia - Mhaskar, R - 2014 | Cochrane Library</title> <meta content="Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia - Mhaskar, R - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003039.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia - Mhaskar, R - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003039.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003039.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia" name="citation_title"/> <meta content="Rahul Mhaskar" name="citation_author"/> <meta content="University of South Florida" name="citation_author_institution"/> <meta content="Otavio Augusto Camara Clark" name="citation_author"/> <meta content="Evidências- A Kantar Health Company" name="citation_author_institution"/> <meta content="otavioclark@yahoo.com" name="citation_author_email"/> <meta content="Gary Lyman" name="citation_author"/> <meta content="Fred Hutchinson Cancer Research Center" name="citation_author_institution"/> <meta content="Tobias Engel Ayer Botrel" name="citation_author"/> <meta content="Evidence Based Medicine Consultancy" name="citation_author_institution"/> <meta content="Luciano Morganti Paladini" name="citation_author"/> <meta content="Evidências" name="citation_author_institution"/> <meta content="Benjamin Djulbegovic" name="citation_author"/> <meta content="University of South Florida &amp; Mofftt Cancer Center" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD003039.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/10/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003039.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003039.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003039.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti-Bacterial Agents [therapeutic use]; Chemotherapy-Induced Febrile Neutropenia [*drug therapy]; Colony-Stimulating Factors [therapeutic use]; Drug Therapy, Combination; Fever [chemically induced, drug therapy]; Granulocyte Colony-Stimulating Factor [*therapeutic use]; Granulocyte-Macrophage Colony-Stimulating Factor [*therapeutic use]; Neoplasms [drug therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003039.pub2&amp;doi=10.1002/14651858.CD003039.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="fw9sVDQH";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003039\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003039\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","hr","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003039.pub2",title:"Colony\\u2010stimulating factors for chemotherapy\\u2010induced febrile neutropenia",firstPublishedDate:"Oct 30, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=fw9sVDQH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003039.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003039.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003039.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003039.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003039.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003039.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003039.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003039.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003039.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003039.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6646 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003039.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/full#CD003039-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/full#CD003039-sec-0076"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/full#CD003039-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/full#CD003039-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/full#CD003039-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/full#CD003039-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/full#CD003039-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/full#CD003039-sec-0070"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/appendices#CD003039-sec-0081"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/table_n/CD003039StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/table_n/CD003039StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/information#CD003039-cr-0004">Rahul Mhaskar</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/information#CD003039-cr-0005"><i class="icon corresponding-author fa fa-envelope"></i>Otavio Augusto Camara Clark</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/information#CD003039-cr-0006">Gary Lyman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/information#CD003039-cr-0007">Tobias Engel Ayer Botrel</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/information#CD003039-cr-0008">Luciano Morganti Paladini</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003039.pub2/information#CD003039-cr-0009">Benjamin Djulbegovic</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/information/en#CD003039-sec-0092">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 October 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003039.pub2">https://doi.org/10.1002/14651858.CD003039.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003039-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003039-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003039-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003039-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003039-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003039-abs-0001" lang="en"> <section id="CD003039-sec-0001"> <h3 class="title" id="CD003039-sec-0001">Background</h3> <p>Febrile neutropenia is a frequent adverse event experienced by people with cancer who are undergoing chemotherapy, and is a potentially life‐threatening situation. The current treatment is supportive care plus antibiotics. Colony‐stimulating factors (CSFs), such as granulocyte‐CSF (G‐CSF) and granulocyte‐macrophage CSF (GM‐CSF), are cytokines that stimulate and accelerate the production of one or more cell lines in the bone marrow. Clinical trials have addressed the question of whether the addition of a CSF to antibiotics could improve outcomes in individuals diagnosed with febrile neutropenia. However, the results of these trials are conflicting. </p> </section> <section id="CD003039-sec-0002"> <h3 class="title" id="CD003039-sec-0002">Objectives</h3> <p>To evaluate the safety and efficacy of adding G‐CSF or GM‐CSF to standard treatment (antibiotics) when treating chemotherapy‐induced febrile neutropenia in individuals diagnosed with cancer. </p> </section> <section id="CD003039-sec-0003"> <h3 class="title" id="CD003039-sec-0003">Search methods</h3> <p>We conducted the search in March 2014 and covered the major electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, LILACS, and SCI. We contacted experts in hematology and oncology and also scanned the citations from the relevant articles. In addition, we also searched for economic evaluations via MEDLINE(R) In‐Process &amp; Other Non‐Indexed Citations, Embase, CENTRAL and NHS Economic Evaluation Database in May 2015 to support a Brief Economic Commentary (BEC). </p> </section> <section id="CD003039-sec-0004"> <h3 class="title" id="CD003039-sec-0004">Selection criteria</h3> <p>We searched for randomized controlled trials (RCTs) and economic evaluations that compared CSF plus antibiotics versus antibiotics alone for the treatment of chemotherapy‐induced febrile neutropenia in adults and children. </p> </section> <section id="CD003039-sec-0005"> <h3 class="title" id="CD003039-sec-0005">Data collection and analysis</h3> <p>We used the standard methodological procedures expected by The Cochrane Collaboration. We performed meta‐analysis of the selected studies using Review Manager 5 software. </p> </section> <section id="CD003039-sec-0006"> <h3 class="title" id="CD003039-sec-0006">Main results</h3> <p>Fourteen RCTs (15 comparisons) including a total of 1553 participants addressing the role of CSF plus antibiotics in febrile neutropenia were included. Overall mortality was not improved by the use of CSF plus antibiotics versus antibiotics alone (hazard ratio (HR) 0.74 (95% confidence interval (CI) 0.47 to 1.16) P = 0.19; 13 RCTs; 1335 participants; low quality evidence). A similar finding was seen for infection‐related mortality (HR 0.75 (95% CI 0.47 to 1.20) P = 0.23; 10 RCTs; 897 participants; low quality evidence). Individuals who received CSF plus antibiotics were less likely to be hospitalized for more than 10 days (risk ratio (RR) 0.65 (95% CI 0.44 to 0.95) P = 0.03; 8 RCTs; 1221 participants; low quality evidence) and had more number of participants with a more faster neutrophil recovery (RR 0.52 (95% CI 0.34 to 0.81) P = 0.004; 5 RCTs; 794 participants; moderate quality evidence) than those treated with antibiotics alone. Similarly, participants receiving CSF plus antibiotics had shorter duration of neutropenia (standardized mean difference (SMD) ‐1.70 (95% CI ‐2.65 to ‐0.76) P = 0.0004; 9 RCTs; 1135 participants; moderate quality evidence), faster recovery from fever (SMD ‐0.49 (95% CI ‐0.90 to ‐0.09) P value = 0.02; 9 RCTs; 966 participants; moderate quality evidence) and shorter duration of antibiotics use (SMD ‐1.50 (95% CI ‐2.83 to ‐0.18) P = 0.03; 3 RCTs; 457 participants; low quality evidence) compared with participants receiving antibiotics alone. We found no significant difference in the incidence of deep venous thromboembolism (RR 1.68 (95% CI 0.72 to 3.93) P = 0.23; 4 RCTs; 389 participants; low quality evidence) in individuals treated with CSF plus antibiotics compared with those treated with antibiotics alone. We found higher incidence of bone or joint pain or flu‐like symptoms (RR 1.59 (95% CI 1.04 to 2.42) P = 0.03; 6 RCTs; 622 participants; low quality evidence) in individuals treated with CSF plus antibiotics compared with those treated with antibiotics alone. Overall, the methodological quality of studies was moderate to low across different outcomes. The main reasons to downgrade the quality of evidence were inconsistency across the included studies and imprecision of results. No full economic evaluations were identified. Several of the included RCTs identified economic benefits regarding a reduction in overall length of stay attributable to the use of CSF plus antibiotics, however they fell short of undertaking a full economic evaluation. </p> </section> <section id="CD003039-sec-0007"> <h3 class="title" id="CD003039-sec-0007">Authors' conclusions</h3> <p>The use of a CSF plus antibiotics in individuals with chemotherapy‐induced febrile neutropenia had no effect on overall mortality, but reduced the amount of time participants spent in hospital and improved their ability to achieve neutrophil recovery. It was not clear whether CSF plus antibiotics had an effect on infection‐related mortality. Participants receiving CSFs had shorter duration of neutropenia, faster recovery from fever and shorter duration of antibiotics use. The current scarcity of relevant economic evaluations highlights an evidence gap and the need for further research fully explore the cost‐effectiveness of these treatment alternatives. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003039-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003039-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003039-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003039-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003039-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003039-abs-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003039-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003039-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003039-abs-0002" lang="en"> <h3>Does administering colony‐stimulating factors plus antibiotics in people with fever and low white cell count reduce hospitalization? </h3> <p><b>Background:</b> People undergoing chemotherapy often experience febrile neutropenia, characterized by a high temperature combined with a low white blood cell count. Febrile neutropenia is a potentially life‐threatening condition and requires prompt medical intervention. The standard treatment for febrile neutropenia includes supportive care of fluids, electrolytes (any substance that contains free ions that can conduct electricity given either intravenously or orally) and antibiotics given either orally or intravenously.<b>Review question:</b> Whether colony‐stimulating factors (CSFs) (hormones that stimulate the production of white blood cells) added to antibiotics are better than antibiotics alone in the treatment of febrile neutropenia caused by cancer chemotherapy?<br/><b>Literature</b> <b>search date:</b> March 2014 and May 2015 for the economic evaluation. <b>Main findings:</b> We identified 14 randomized controlled trials (RCTs) enrolling a total of 1553 participants. Six trials were funded by industry alone and 3 trials were jointly funded by industry and public sources and only 1 trial was funded by public sources alone. Our study shows that although CSFs do not appear to improve survival, they shorten the amount of time a person spends in hospital and increase their chances that white blood cells will recover to normal levels. It is not clear whether the use of a CSF reduces the number of people who die due to infection. Our study shows that CSFs shorten the time taken for the white blood cells to return to normal levels, recovery from fever and stopping antibiotics. The number of patients suffering from treatment related harms such as blood clots in the veins were similar between patients receiving CSF and antibiotics and antibiotics alone. The number of patients experiencing bone or joint pain or flu‐like symptoms was higher among individuals receiving CSF and antibiotics compared with individuals receiving antibiotics alone. No economic evaluations were identified. Several of the included RCTs identified economic benefits regarding a reduction in overall length of stay attributable to the use of CSF plus antibiotics, however they fell short of undertaking a full economic evaluation. <b>Quality of the evidence:</b> The overall methodological quality of included studies was moderate to low. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003039-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003039-sec-0076"></div> <h3 class="title" id="CD003039-sec-0077">Implications for practice</h3> <section id="CD003039-sec-0077"> <p>The use of CSF plus antibiotics in people with chemotherapy‐induced febrile neutropenia was not found to improve overall survival compared with antibiotics alone but did reduce the time participants spent in hospital and the duration neutropenia, time to recovering from fever and time to withdrawal from antibiotics. The people receiving CSF plus antibiotics also had a faster neutrophil recovery compared with people receiving antibiotics alone. The incidence of adverse events with CSF in addition to antibiotics appear to be similar compared with antibiotics alone. The impact of CSF plus antibiotics on infection‐related mortality was not clear. </p> </section> <h3 class="title" id="CD003039-sec-0078">Implications for research</h3> <section id="CD003039-sec-0078"> <p>Following these results, it is unlikely that future trials will feature a no‐treatment control group. To assess the effect of CSF plus antibiotics on mortality therefore, an individual patient data analysis is highly desirable. The current scarcity of relevant economic evaluations highlights an evidence gap and the need for further research fully explore the cost‐effectiveness of these treatment alternatives. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003039-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003039-sec-0008"></div> <div class="table" id="CD003039-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Benefits and harms of CSF plus antibiotics versus antibiotics alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CSF plus ATB compared to ATB alone for chemotherapy induced febrile neutropenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> people with chemotherapy‐induced febrile neutropenia<br/><b>Settings:</b> in‐patient/hospital<br/><b>Intervention:</b> CSF plus ATB<br/><b>Comparison:</b> ATB alone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>ATB alone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>CSF + ATB</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Overall mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>HR 0.74</b> <br/>(0.47 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1335<br/>(13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b><br/>(33 to 80) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(14 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Infection‐related mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.75</b> <br/>(0.47 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>897<br/>(10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b><br/>(27 to 67) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b><br/>(10 to 26) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>People hospitalized for &gt; 10 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.65</b> <br/>(0.44 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1087<br/>(7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>349 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b><br/>(153 to 331) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>338 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>220 per 1000</b><br/>(149 to 321) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of grade IV neutropenia</b> (lower values signify better outcomes) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>The mean duration of grade IV neutropenia in the intervention groups was<br/><b>1.70 standard deviations lower</b><br/>(2.65 to 0.76 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SMD ‐1.70</b> </p> <p>(‐2.65 to ‐0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1135<br/>(9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>3,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to recovery from fever</b> </p> <p>(lower values signify better outcomes)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>The mean time to recovery from fever in the intervention groups was<br/><b>0.49 standard deviations lower</b><br/>(0.9 to 0.09 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SMD ‐0.49</b> </p> <p>(‐0.9 to ‐0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>966<br/>(9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>3,6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to withdrawal from ATB</b> </p> <p>(lower values signify better outcomes)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>The mean time to withdrawal from ATB in the intervention groups was<br/><b>1.5 standard deviations lower</b><br/>(2.83 to 0.18 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SMD ‐1.5</b> </p> <p>(‐2.83 to ‐0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>457<br/>(3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>3,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Deep vein thrombosis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.68</b> <br/>(0.72 to 3.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>389<br/>(4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b><br/>(18 to 101) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/>(4 to 20) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ATB:</b> antibiotics; <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RR:</b> risk ratio; <b>SMD</b>: standardized mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Seven of the included articles described an adequate method of randomization (<a href="./references#CD003039-bbs2-0001" title="AnaissieEJ , VartivarianS , BodeyGP , LegrandC , KantarjianH , Abi-SaidD , et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. The American Journal of Medicine1996;100(1):17-23. ">Anaissie 1996</a>; <a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>; <a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0006" title="Lopez-HernandezMA , Jimenez-AlvaradoR , Borbolla-EscobozaR , deDiego Flores-ChapaJ , Alvarado-IbarraM , Gonzalez-AvanteM , et al. Granulocyte colony-stimulating factor in the treatment of febrile neutropenia. Gaceta Médica de México2000;136(2):99-105. ">Lopez‐Hernandez 2000</a>; <a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>; <a href="./references#CD003039-bbs2-0014" title="YoshidaM , KarasawaM , NaruseT , FukudaM , HirashimaK , OhH , et al. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. International Journal of Hematology1999;69(2):81-8. ">Yoshida 1999</a>) and five reported adequate concealment of the sequence of allocation (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>; <a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>). Seven trials were placebo controlled (<a href="./references#CD003039-bbs2-0002" title="ArnbergH , LetochaH , NouF , WestlinJF , NilssonS . GM-CSF in chemotherapy-induced febrile neutropenia - a double-blind randomized study. Anticancer Research1998;18(2B):1255-60. ">Arnberg 1998</a>; <a href="./references#CD003039-bbs2-0004" title="BiesmaB , deVriesEG , WillemsePH , SluiterWJ , PostmusPE , LimburgPC , et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer1990;26(9):932-6. ">Biesma 1990</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>). A sample size was preplanned in seven (<a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>; <a href="./references#CD003039-bbs2-0012" title="RodriguezZN , TordecillaCJ , CampbellBM , JoannonSP , RizzardiniLC , SotoAV , et al. Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia [Utilidad del factor estimulador de colonias de granulocitos (G-CSF) en episodios de neutropenia febril de alto riesgo en ninos con cancer.]. Revista Chilena de Infectologia2005;22(3):223-7. [PMID: 16077888]">Rodriguez 2005</a>), but the planned number was not reached in one trial (<a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>). Hence we downgraded the quality of evidence by 1 for the risk of bias (also see footnote # 2 below).<br/><sup>2</sup> Of all the included trials only that by Aviles et al (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>) appeared to show a benefit of CSF plus antibiotics compared with antibiotics alone for the outcome of overall mortality. It is important to note that 33% (15 of 45) of the events for this outcome in the control group were reported in this trial. These 15 deaths represent 33% (15 of 45) of the total of deaths in the control group among all trials. Similarly, there were 15 infection‐related deaths among the 471 participants randomized to the intervention group and 25 among 426 randomized to the control group. However, it is important to note that 60% (15 of 25) of the events in the control group were reported in one study (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>).<br/><sup>3</sup> A majority of the individual randomized controlled trials and the pooled estimates have wide CIs. We downgraded the quality of evidence by 1 for the observed imprecision. </p> <p><sup>4</sup> Substantial heterogeneity was detected (P = 0.0009, I<sup>2</sup> = 70%). As planned, we explored the possible causes of heterogeneity to determine if it was appropriate to pool the trials. All trials but one trial (<a href="./references#CD003039-bbs2-0014" title="YoshidaM , KarasawaM , NaruseT , FukudaM , HirashimaK , OhH , et al. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. International Journal of Hematology1999;69(2):81-8. ">Yoshida 1999</a>) had a point estimate that favored the intervention group. This trial enrolled only people with hematological malignancies. We explored the impact of type of malignancy on number of participants hospitalized for more than 10 days (<a href="#CD003039-sec-0039">Subgroup analysis and investigation of heterogeneity</a>: type of malignancy). The trials enrolling people with mixed cancers favored the use of CSF plus antibiotics (RR 0.64, 95% CI 0.45 to 0.89) compared with trial enrolling people with only hematological malignancies (RR 1.17, 95% CI 0.81 to 1.70) (test of interaction P = 0.02) for the outcome of number of participants hospitalized for more than 10 days (<a href="./references#CD003039-fig-0025" title="">Analysis 5.1</a>). We also noticed that only two trials reached statistical significance (<a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>). By inspecting the forest plot, we could detect that trial by Mayordomo et al (<a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>) and Maher et al (<a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>) indicated a much stronger effect than that detected in all other trials. We therefore repeated our analysis, excluding these trials (<a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>). The exclusion resulted in a substantial reduction in the statistical heterogeneity (I<sup>2</sup> = 48%; P = 0.10) and the significance of the effect of CSF plus antibiotics on this outcome disappeared (RR 0.85, 95% CI = 0.61 to 1.17; P = 0.32). Hence we downgraded the quality of evidence by 1 for the observed inconsistency. </p> <p><sup>5</sup> Considerable heterogeneity was detected (P value &lt; 0.00001, I<sup>2</sup> = 98%). In a subgroup analysis according to CSF type, G‐CSF showed a statistically significantly stronger beneficial effect than GM‐CSF for the outcome of duration of grade IV neutropenia (<a href="./references#CD003039-fig-0018" title="">Analysis 3.3</a>). Nonetheless, we downgraded the quality of evidence by 1 for the observed inconsistency. </p> <p><sup>6</sup> Considerable heterogeneity was detected (P value &lt; 0.00001, I<sup>2</sup> = 89%). We downgraded the quality of evidence by 1 for the observed inconsistency. </p> <p><sup>7</sup> Considerable heterogeneity was detected (P value &lt; 0.00001, I<sup>2</sup> = 97%). We downgraded the quality of evidence by 1 for the observed inconsistency. We noted that in all of these trials the mean/median duration of ATB use was similar (mean of 5 days) among patients receiving CSF. However, the high precision observed around the effect size in the trial by Garcio‐Carbonero et al (<a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>) compared with other two trial estimates was potentially leading to the substantial heterogeneity. The heterogeneity disappeared completely once we removed this trial from the analysis (P value = 0.72, I<sup>2</sup> = 0%) and the overall effect still showed benefit with the use of CSF plus ATB compared with ATB alone. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003039-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003039-sec-0009"></div> <section id="CD003039-sec-0010"> <h3 class="title" id="CD003039-sec-0010">Description of the condition</h3> <p>Febrile neutropenia is a relatively frequent event in people with cancer receiving chemotherapy. It is a potentially life‐threatening condition and requires prompt medical intervention (<a href="./references#CD003039-bbs2-0075" title="PizzoPA . Fever in immunocompromised patients. The New England Journal of Medicine1999;341(12):893-900.">Pizzo 1999</a>). Febrile neutropenia is one of the most concerning complications of cancer chemotherapy and is a major cause of morbidity, healthcare resource use and compromised efficacy resulting from delays and dose reductions in chemotherapy. Mortality from febrile neutropenia has diminished steadily but remains significant. Overall mortality rates are around 5% in people with solid tumours (1% in low‐risk people) and as high as 11% in people diagnosed with some hematological malignancies. Prognosis is worst in people with proven bacteremia, with mortality rates of 18% and 5% reported in people with Gram‐negative and Gram‐positive bacteremia, respectively. Elderly people are at a higher risk of febrile neutropenia following chemotherapy, with worse morbidity and mortality rates (<a href="./references#CD003039-bbs2-0049" title="deNauroisJ , Novitzky-BassoI , GillMJ , MartiFM , CullenMH , RoilaF , et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Annals of Oncology2010;21 Suppl 5:v252-v6.">de Naurois 2010</a>). </p> <p>Chemotherapy‐induced febrile neutropenia is a potentially life‐threatening complication for which the incidence and mortality varies according to cancer type and chemotherapy regimen. The economic burden of the complication has been estimated in the literature, however, estimated costs are variable. One study suggests that for solid tumour patients within a routine oncology hospital setting the average cost per episode is $3855<sup>*</sup> (2013 US$) (<sup>*</sup>adjusted from 2007 GBP to 2014 US$ using CCEMG‐EPPI cost conversion tool (<a href="http://eppi.ioe.ac.uk/costconversion/default.aspx" target="_blank">http://eppi.ioe.ac.uk/costconversion/default.aspx</a>) (<a href="./references#CD003039-bbs2-0078" title="SchelenzS , GilesD , AbdallahS . Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. Annals of Oncology2012;23(7):1889-93.">Schelenz 2012</a>) whilst a review of cost‐of‐illness studies in lymphoma patients experiencing febrile neutropenia found large variation in the cost estimates ranging from $5819 to $34,756 (2013 US$) per episode (<a href="./references#CD003039-bbs2-0082" title="WangXJ , LopezSE , Chan A Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review. Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review. Critical Reviews in Oncology / Hematology2015;94(2):201-12.">Wang 2015</a>) </p> </section> <section id="CD003039-sec-0011"> <h3 class="title" id="CD003039-sec-0011">Description of the intervention</h3> <p>The standard treatment for febrile neutropenia includes supportive care plus broad‐spectrum antibiotics (<a href="./references#CD003039-bbs2-0075" title="PizzoPA . Fever in immunocompromised patients. The New England Journal of Medicine1999;341(12):893-900.">Pizzo 1999</a>). There is no consensus in the literature as to which antibiotics or combination of antibiotics is ideal for the treatment for febrile neutropenia (<a href="./references#CD003039-bbs2-0054" title="GiamarellouH , AntoniadouA . Infectious complications of febrile leukopenia. Infectious Disease Clinics of North America2001;15(2):457-82.">Giamerellou 2001</a>). Hematopoietic growth‐stimulating factors are a class of cytokines that regulate the proliferation, differentiation, and functions of hematopoietic cells (<a href="./references#CD003039-bbs2-0056" title="GriffinJD . Hematopoietic growth factors. In: DeVitaJrVT , HellmanS , RosenbergSA , editors(s). Cancer: Principles and Practice of Oncology. 6th edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2001.">Griffin 2001</a>). More than 20 different types of stimulating factor have been identified (<a href="./references#CD003039-bbs2-0056" title="GriffinJD . Hematopoietic growth factors. In: DeVitaJrVT , HellmanS , RosenbergSA , editors(s). Cancer: Principles and Practice of Oncology. 6th edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2001.">Griffin 2001</a>) and many have been tested in clinical studies for different applications (<a href="./references#CD003039-bbs2-0056" title="GriffinJD . Hematopoietic growth factors. In: DeVitaJrVT , HellmanS , RosenbergSA , editors(s). Cancer: Principles and Practice of Oncology. 6th edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2001.">Griffin 2001</a>; <a href="./references#CD003039-bbs2-0079" title="SegalBH , WalshTJ , HollandSM . Infections in the cancer patient. In: DeVitaJrVT , HellmanS , RosenbergSA , editors(s). Cancer: Principles and Practice of Oncology. 6th edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2001.">Segal 2001</a>). Among them, granulocyte colony‐stimulating factor (G‐CSF) and granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) have been studied in people with cancer because of their potential effect on neutropenia. </p> </section> <section id="CD003039-sec-0012"> <h3 class="title" id="CD003039-sec-0012">How the intervention might work</h3> <p>G‐CSF regulates the production of the neutrophil lineage. The administration of G‐CSF to humans results in a dose‐dependent increase in circulating neutrophils (<a href="./references#CD003039-bbs2-0056" title="GriffinJD . Hematopoietic growth factors. In: DeVitaJrVT , HellmanS , RosenbergSA , editors(s). Cancer: Principles and Practice of Oncology. 6th edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2001.">Griffin 2001</a>; <a href="./references#CD003039-bbs2-0074" title="PetrosWP . Colony-stimulating factors. In: ChabnerBA , LongoDL , editors(s). Cancer Chemotherapy and Biotherapy - Principles and Practice. 5th edition. Lippincott Williams &amp; Wilkins, 2001.">Petros 2001</a>), due mainly to a reduction in transit time from stem cell to mature neutrophil (<a href="./references#CD003039-bbs2-0056" title="GriffinJD . Hematopoietic growth factors. In: DeVitaJrVT , HellmanS , RosenbergSA , editors(s). Cancer: Principles and Practice of Oncology. 6th edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2001.">Griffin 2001</a>). GM‐CSF stimulates the growth of granulocyte, macrophage and eosinophil colonies (<a href="./references#CD003039-bbs2-0056" title="GriffinJD . Hematopoietic growth factors. In: DeVitaJrVT , HellmanS , RosenbergSA , editors(s). Cancer: Principles and Practice of Oncology. 6th edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2001.">Griffin 2001</a>; <a href="./references#CD003039-bbs2-0074" title="PetrosWP . Colony-stimulating factors. In: ChabnerBA , LongoDL , editors(s). Cancer Chemotherapy and Biotherapy - Principles and Practice. 5th edition. Lippincott Williams &amp; Wilkins, 2001.">Petros 2001</a>). The administration of GM‐CSF to humans results in a dose‐dependent increase in blood neutrophils, eosinophils, macrophages and sometimes lymphocytes (<a href="./references#CD003039-bbs2-0056" title="GriffinJD . Hematopoietic growth factors. In: DeVitaJrVT , HellmanS , RosenbergSA , editors(s). Cancer: Principles and Practice of Oncology. 6th edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2001.">Griffin 2001</a>; <a href="./references#CD003039-bbs2-0074" title="PetrosWP . Colony-stimulating factors. In: ChabnerBA , LongoDL , editors(s). Cancer Chemotherapy and Biotherapy - Principles and Practice. 5th edition. Lippincott Williams &amp; Wilkins, 2001.">Petros 2001</a>). Different types of G‐CSF and GM‐CSF have been tested in clinical trials and are available. Among the most used G‐CSFs are filgrastim and lenograstim, and among the most used GM‐CSFs are sargramostim and molgramostim. Both G‐CSFs and GM‐CSFs have been demonstrated to be effective in reducing the incidence of febrile neutropenia when given immediately after chemotherapy (<a href="./references#CD003039-bbs2-0053" title="FreyerG , LigneauB , Trillet-LenoirV . Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia. International Journal of Antimicrobial Agents1998;10(1):3-9.">Freyer 1998</a>; <a href="./references#CD003039-bbs2-0070" title="LymanGH , KudererNM , DjulbegovicB . Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. The American Journal of Medicine2002;112(5):406-11.">Lyman 2002</a>) and as supportive therapy in people undergoing bone marrow transplantation (<a href="./references#CD003039-bbs2-0056" title="GriffinJD . Hematopoietic growth factors. In: DeVitaJrVT , HellmanS , RosenbergSA , editors(s). Cancer: Principles and Practice of Oncology. 6th edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins, 2001.">Griffin 2001</a>; <a href="./references#CD003039-bbs2-0074" title="PetrosWP . Colony-stimulating factors. In: ChabnerBA , LongoDL , editors(s). Cancer Chemotherapy and Biotherapy - Principles and Practice. 5th edition. Lippincott Williams &amp; Wilkins, 2001.">Petros 2001</a>). The known effect of G‐CSF and GM‐CSF in increasing the number of circulating neutrophils provided the background for clinical studies designed to assess their role as adjunct therapy to antibiotics in people diagnosed with febrile neutropenia. </p> </section> <section id="CD003039-sec-0013"> <h3 class="title" id="CD003039-sec-0013">Why it is important to do this review</h3> <p>The results of randomized controlled trials (RCTs) addressing the role of CSFs in the management of febrile neutropenia have not been clear and conflicting findings have been published. Whereas two studies found no significant effect of CSFs in the prevention of prolonged hospitalization (<a href="./references#CD003039-bbs2-0001" title="AnaissieEJ , VartivarianS , BodeyGP , LegrandC , KantarjianH , Abi-SaidD , et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. The American Journal of Medicine1996;100(1):17-23. ">Anaissie 1996</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>), Another reported CSFs to have a significant impact on length of hospitalization (<a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>). Time to recovery from fever was favorably affected by CSF in two studies (<a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>) but not in another (<a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>). Also, different results regarding the use of CSFs have been reported in people classified as having a low or high baseline risk of developing a life‐threatening complication (<a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>). Individually, these studies included fewer than 220 participants, and this factor, in addition to reported low rates of clinical events such as death, means that they may have been underpowered to detect a difference between the treated groups. Conflicting results obtained from small studies demands the conduct of a systematic review of the literature (<a href="./references#CD003039-bbs2-0052" title="EggerM , SmithGD , AltmanD . Systematic Reviews in Health Care. 2nd edition. London: BMJ Books, 2001.">Egger 2001</a>) in order to extend the totality of evidence to allow informed medical decision. Accordingly, in 2000, we conducted and published a Cochrane systematic review addressing the role of CSF plus antibiotics versus antibiotics alone in individuals with chemotherapy‐induced febrile neutropenia (<a href="./references#CD003039-bbs2-0083" title="ClarkOA , LymanG , CastroAA , ClarkLG , DjulbegovicB . Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database of Systematic Reviews2000;(3). [DOI: 10.1002/14651858.CD003039] [CD003039]">Clark 2000</a>). However, since the publication of this review, further RCTs in this area have been published. This gave us an impetus to update our previous systematic review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003039-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003039-sec-0014"></div> <p>To evaluate the safety and efficacy of adding G‐CSF or GM‐CSF to standard treatment (antibiotics) when treating chemotherapy‐induced febrile neutropenia in individuals diagnosed with cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003039-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003039-sec-0015"></div> <section id="CD003039-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003039-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included all randomized controlled trials (RCTs) with a parallel design that compared the use of a CSF plus antibiotics versus antibiotics alone for the treatment of individuals with established chemotherapy‐induced febrile neutropenia. We also looked for full economic evaluations. </p> </section> <section id="CD003039-sec-0018"> <h4 class="title">Types of participants</h4> <p>Individuals undergoing chemotherapy for cancer who experienced neutropenia (absolute neutrophil count (ANC) less than 1 x 10<sup>9</sup>/L (1000/mm<sup>3</sup>)) and fever (body temperature higher than 38.5°C on one occasion or higher than 38°C on two or more occasions). </p> </section> <section id="CD003039-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Intervention group: G‐CSF or GM‐CSF plus antibiotics</p> <p>Control group: antibiotics plus no further treatment or placebo</p> </section> <section id="CD003039-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD003039-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003039-list-0001"> <li> <p>Overall mortality</p> </li> <li> <p>Infection‐related mortality</p> </li> </ul> </p> </section> <section id="CD003039-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003039-list-0002"> <li> <p>Number of people hospitalized for more than 10 days</p> </li> <li> <p>Time to neutrophil recovery (number of people with neutropenia (ANC &lt; 1000/mm<sup>3</sup>) for more than 5 to 10 days) </p> </li> <li> <p>Duration (measured in days) of grade IV neutropenia (ANC &lt; 500/mm<sup>3</sup>) </p> </li> <li> <p>Time to recovery from fever</p> </li> <li> <p>Time to withdrawal from antibiotics</p> </li> <li> <p>Time to defervescence (the abatement of a fever due to a decrease in body temperature)</p> </li> <li> <p>Treatment‐related harms, including deep vein thrombosis (DVT) and bone, joint pain or flu like symptoms </p> </li> </ul> </p> </section> </section> </section> <section id="CD003039-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003039-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We performed a wide search on the main computerized databases of interest. For the original review, the search dates were: the Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 1, 2003), MEDLINE (1966 to 2002), EMBASE (1974 to 2001), LILACS (1980 to 2003), CANCERLIT (1975 to 2002), and SCI (1974 to 2001). </p> <p>For this update, we extended the searches to: CENTRAL (Issue 3 of 12, March 2014; searched 25 March 2014), MEDLINE (2002 to 2014; searched 25 March 2014), EMBASE (2001 to 2014), LILACS (2014), CANCERLIT (2002 to 2004; now incorporated into MEDLINE), and SCI (2001 to 2014). </p> <p>For MEDLINE, we used the methodological search strategy for RCTs (<a href="./references#CD003039-bbs2-0050" title="DickersinK , SchererR , LefebvreC . Identifying relevant studies for systematic reviews. BMJ1994;309(6964):1286-91.">Dickersin 1994</a>) recommended by The Cochrane Collaboration (<a href="./references#CD003039-bbs2-0063" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.. Available from www.cochrane-handbook.org.">Higgins 2011a</a>). For EMBASE, we used adaptations of this same strategy and for LILACS we used the methodological search strategy reported by <a href="./references#CD003039-bbs2-0048" title="CastroAA , ClarkOA , AtallahAN . Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. Sao Paulo Medical Journal1999;117(3):138-9.">Castro 1999</a>. We performed an additional search of the SCI database to look for studies that had cited the included studies (see <a href="./appendices#CD003039-sec-0082">Appendix 1</a>; <a href="./appendices#CD003039-sec-0083">Appendix 2</a>; <a href="./appendices#CD003039-sec-0084">Appendix 3</a>; <a href="./appendices#CD003039-sec-0085">Appendix 4</a>; <a href="./appendices#CD003039-sec-0086">Appendix 5</a>; <a href="./appendices#CD003039-sec-0087">Appendix 6</a> for the respective search strategies). </p> <p>The search strategies used have been developed and executed by the author team.</p> <p>For economic evaluations we used the non‐methodological portion of the original search strategies in combination with a economic evaluation filter (<a href="./appendices#CD003039-sec-0088">Appendix 7</a>) for all databases except NHS EED since this database only contains economic evaluation citations.The following databases were searched: Ovid MEDLINE(R) In‐Process &amp; Other Non‐Indexed Citations and Ovid MEDLINE(R)1946 to May 2015, Embase 1974 to 2015 Week 24, EBM Reviews ‐ Cochrane Central Register of Controlled Trials May 2015 and EBM Reviews ‐ NHS Economic Evaluation Database 2nd Quarter 2015. </p> </section> <section id="CD003039-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We scanned all the references of relevant articles and retrieved all additional articles of potential interest for further analysis.<br/>We consulted experts in oncology and hematology about ongoing studies or studies that have not yet been published. We also scanned the personal collections of articles of two of the authors (GL and BD). </p> </section> </section> <section id="CD003039-sec-0026"> <h3 class="title" id="CD003039-sec-0026">Data collection and analysis</h3> <section id="CD003039-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (OACC and RM) independently scanned the retrieved titles and abstracts of all studies for their eligibility for inclusion in the systematic review. We resolved any disagreements in the selection of studies by consensus (<a href="./references#CD003039-bbs2-0064" title="HigginsJPT , DeeksJJ . Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011b</a>). At every stage of searching and screening, we documented the overall number of studies identified, excluded, and included, with reasons, according to the preferred reporting items for systematic reviews and meta‐analyses (PRISMA) guidelines, which we also used to create a flow diagram (<a href="./references#CD003039-bbs2-0072" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Journal of Clinical Epidemiology2009;62(10):1006-12.">Moher 2009</a>). </p> </section> <section id="CD003039-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (OACC and RM) independently extracted data using a standardized data extraction form. From each relevant trial, we retrieved data on the selected clinical outcomes, methodological characteristics, and types of participants in each study. Specifically we extracted data on the following. </p> <section id="CD003039-sec-0029"> <h5 class="title">Clinical outcomes</h5> <p> <ul id="CD003039-list-0003"> <li> <p>Mortality ‐ overall and infection related</p> </li> <li> <p>Number of people hospitalized for more than 10 days</p> </li> <li> <p>Time to neutrophil recovery (number of people with neutropenia (ANC &lt; 1000/mm<sup>3</sup>) for more than 5 to 10 days) </p> </li> <li> <p>Duration of grade IV neutropenia (Data reported in individual studies as either median days to recovery to ANC &gt; 500/mm<sup>3</sup> or median days of grade IV neutropenia: ANC &lt; 500/mm<sup>3</sup>) </p> </li> <li> <p>Time to recovery from fever</p> </li> <li> <p>Time to withdrawal from antibiotics</p> </li> <li> <p>Time to defervescence (the abatement of a fever due to a decrease in body temperature)</p> </li> <li> <p>Treatment‐related harms, including deep DVT and bone, joint pain or flu like symptoms</p> </li> </ul> </p> </section> <section id="CD003039-sec-0030"> <h5 class="title">Additional data</h5> <p> <ul id="CD003039-list-0004"> <li> <p>General information on the study: authors, date of publication, title, publication type (full text, abstract, unpublished), number of centers involved, and funding source </p> </li> <li> <p>Study characteristics: inclusion/exclusion criteria, length of follow up, diagnostic criteria for neutropenia (ANC), criteria for hospital discharge </p> </li> <li> <p>Participant characteristics: age, adults versus children, gender, number of participants recruited/allocated/evaluated, participants lost to follow up, type of tumour (solid versus hematological) </p> </li> <li> <p>Intervention: detailed description of both the intervention and standard treatment in terms of: </p> <ul id="CD003039-list-0005"> <li> <p>type of CSF used with dosage and duration;</p> </li> <li> <p>type of antibiotics used with dosage and duration</p> </li> </ul> </li> </ul> </p> <p>Studies reported data for the outcome of time to neutrophil recovery in the form of number of participants with neutropenia for more than 5 to 10 days. Accordingly, we extracted data in the form of number of participants with neutropenia for 5 to 10 days in both the experimental and control arms and have reported risk ratio (RR) and 95% confidence intervals (CIs). </p> <p>Studies reported data for the outcome of duration of grade IV neutropenia in the form of median days to recovery to ANC &gt; 500/mm<sup>3</sup> or median days of grade IV neutropenia: ANC &lt; 500/mm<sup>3</sup>. Accordingly, we extracted data in the form of mean and standard deviation of duration of neutropenia in both the experimental and control arms and have reported standardized mean difference (SMD) and 95%CIs. </p> <p>When time‐to‐event data were not available for direct extraction, we extracted data according to the methods described by Tierney et al (<a href="./references#CD003039-bbs2-0081" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16. [PMID: 17555582]">Tierney 2007</a>). These methods allow the calculation of the hazard ratio (HR) and associated statistics using indirect calculation of the variance and the number of observed minus expected events, based on parameters reported in the included studies (e.g. P values, log‐rank statistics, or survival curves). </p> <p>We extracted details regarding the main methodological dimensions empirically linked to bias (<a href="./references#CD003039-bbs2-0052" title="EggerM , SmithGD , AltmanD . Systematic Reviews in Health Care. 2nd edition. London: BMJ Books, 2001.">Egger 2001</a>) and two review authors assessed the methodological quality of each selected trial. We gave special attention to the generation of randomization sequence, allocation concealment, blinding, use of intention‐to‐treat (ITT) versus per‐protocol analyses, and source of funding. We used these data in sensitivity analyses to test the robustness of our findings. </p> </section> <section id="CD003039-sec-0031"> <h5 class="title">Data management</h5> <p>Two review authors manually extracted data from publications into a standardized data extraction form. A third review author validated the extracted data. We resolved all disagreements at each step by consensus or, where necessary, by consulting a third reviewer. One review author entered data into Review Manager (<a href="./references#CD003039-bbs2-0076" title="Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration2014.">Review Manager 5.3</a>) and another checked the entries for accuracy, consistency, and completeness. Senior review authors randomly reviewed 15% of the data for accuracy. </p> </section> </section> <section id="CD003039-sec-0032"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed all eligible studies for their risk of bias (assessment of methodological quality) using methods suggested in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003039-bbs2-0065" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011c</a>). The summary judgment of the review authors comprised an answer for each risk criterion, based on the following three‐point scale: </p> <p> <ul class="plain" id="CD003039-list-0006"> <li> <ul id="CD003039-list-0007"> <li> <p>yes (low risk of bias: plausible bias unlikely to seriously alter the results if all criteria were met); </p> </li> <li> <p>no (high risk of bias: plausible bias that seriously weakens confidence in the results if one or more criteria were not met); </p> </li> <li> <p>unclear (uncertain risk of bias: plausible bias that raises some doubt about the results if one or more criteria were assessed as unclear). </p> </li> </ul> </li> </ul> </p> <p>The following items were included in the assessment of risk of bias:</p> <p> <ul id="CD003039-list-0008"> <li> <p>sequence generation (whether allocation sequence was adequately generated);</p> </li> <li> <p>allocation concealment (whether allocation was adequately concealed);</p> </li> <li> <p>masking/blinding (whether the knowledge of the allocated intervention was adequately prevented during the study; i.e. we extracted data regarding who (participants, personnel, outcome assessors, data analysts) was blinded); </p> </li> <li> <p>incomplete outcome data (whether incomplete outcome data were adequately addressed);</p> </li> <li> <p>selective outcome reporting (whether reports of the study were free of selective outcome reporting); </p> </li> <li> <p>other sources of bias (whether reports of the study included pre specification of the expected difference in the primary outcome (delta), alpha error, beta error or sample size calculation); </p> </li> <li> <p>ITT analysis (whether ITT analysis was undertaken in the study).</p> </li> </ul> </p> <p>In addition, we assessed whether domains related to random error and sample size were specified <i>a priori</i> in each trial. </p> </section> <section id="CD003039-sec-0033"> <h4 class="title">Measures of treatment effect</h4> <p> <ul id="CD003039-list-0009"> <li> <p>For dichotomous outcomes (e.g. treatment‐related harms), data were summarized as RR with 95% CIs for each trial </p> </li> <li> <p>For time‐to‐event outcome (e.g. overall mortality), data were summarized as HRs and 95% CIs </p> </li> <li> <p>For continuous outcomes (e.g. time to withdrawal from antibiotics), data were summarized as means and standard deviations for each trial. Where data were reported as median and range, we converted these data into mean and standard deviation using the method by Hozo et al (<a href="./references#CD003039-bbs2-0067" title="HozoSP , DjulbegovicB , HozoI . Estimating the mean and variance from the median, range, and the size of a sample. BMC Medical Research Methodology2005;5:13. [PMID: 15840177]">Hozo 2005</a>). </p> </li> </ul> </p> </section> <section id="CD003039-sec-0034"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was a study from which aggregate data were extracted as follows: for dichotomous variables, the number of participants in the 'CSF plus antibiotics' arm (intervention group) and the number of participants in the 'antibiotics alone' arm (control group). For continuous variables, the means, standard deviations, and the numbers of participants in the intervention and control groups were used. For studies with multiple intervention groups, we included each pair‐wise comparison separately. Hence, for dichotomous outcomes, both the number of events and the total number of participants were divided for the control arm (ATB alone). Similarly, for time‐to‐event outcomes, the number of events and the total number of participants were divided for the control arm and the variance and number of observed minus expected events were calculated separately for each comparison. For continuous outcomes, the total number of participants was divided for the control arm, and means and standard deviations were calculated separately for each comparison (<a href="./references#CD003039-bbs2-0066" title="HigginsJPT , AltmanDG , SterneJAC . Chapter 16.5.4: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.">Higgins 2011d</a>). </p> </section> <section id="CD003039-sec-0035"> <h4 class="title">Dealing with missing data</h4> <p>Where necessary outcome data were not available from the primary literature we requested missing data or complementary information from the first or corresponding authors of such publications. </p> </section> <section id="CD003039-sec-0036"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity among trials and between subgroups using a Chi<sup>2</sup> test with a P value of &lt; 0.10 as the level of significance. The degree of heterogeneity among trials and between subgroups was also assessed using the I² statistic. We used the following guide to the interpretation of the I² statistic: I² = 0% to 40%: heterogeneity that might not be important; I² = 30% to 60%: moderate heterogeneity; I² = 50% to 90%: substantial heterogeneity), I² = 75% to 100%: considerable heterogeneity (<a href="./references#CD003039-bbs2-0063" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.. Available from www.cochrane-handbook.org.">Higgins 2011a</a>). The importance of the observed value of I<sup>2</sup> depends on (i) the magnitude and direction of effects and (ii) the strength of evidence for the heterogeneity (e.g. a P value from the Chi<sup>2</sup> test, or the I<sup>2</sup> statistic). When heterogeneity was detected, we searched intensively for a possible explanation. </p> </section> <section id="CD003039-sec-0037"> <h4 class="title">Assessment of reporting biases</h4> <p>We assessed the possibility of publication bias by generating a funnel plot and by conducting a linear regression test using a P value of &lt; 0.1 as the level of significance (<a href="./references#CD003039-bbs2-0051" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta-analysis detected by a simple, graphical test. BMJ1997;315(7109):629-34.">Egger 1997</a>; <a href="./references#CD003039-bbs2-0063" title="HigginsJPT , Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011.. Available from www.cochrane-handbook.org.">Higgins 2011a</a>). </p> </section> <section id="CD003039-sec-0038"> <h4 class="title">Data synthesis</h4> <p>We conducted meta analyses using <a href="./references#CD003039-bbs2-0076" title="Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration2014.">Review Manager 5.3</a> software by the Cochrane Collaboration (<a href="./references#CD003039-bbs2-0076" title="Review Manager (RevMan) [Computer program]. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration2014.">Review Manager 5.3</a>). For the outcomes of number of participants hospitalized for more than 10 days, time to neutrophil recovery (reported as number of people with neutropenia (ANC &lt; 1000/mm<sup>3</sup>) for more than 5 to 10 days), DVT and bone and joint pain, or flu‐like symptoms we calculated the RRs with 95% CIs and pooled the data using the Mantel–Haenszel random‐effects model. For the outcomes of overall mortality and infection‐related mortality we calculated the observed minus expected log‐rank statistics plus the variance, according to the methods described by Tierney et al (<a href="./references#CD003039-bbs2-0081" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16. [PMID: 17555582]">Tierney 2007</a>), and presented the results (pooled using a random effects model and inverse variance method) as HRs (<a href="./references#CD003039-bbs2-0081" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials2007;8:16. [PMID: 17555582]">Tierney 2007</a>). For the outcomes of duration of grade IV neutropenia, time to recovery from fever and time to withdrawal from antibiotics we calculated the standardized mean differences with 95% CIs and pooled the data using the random‐effects model and inverse variance method. We provided a 'Summary of findings' table, produced using Grading of Recommendations Assessment, Development and Evaluation (GRADE) software (<a href="./references#CD003039-bbs2-0055" title="GRADEpro. Version 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008.">GRADEpro</a>; <a href="./references#CD003039-bbs2-0057" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 7. Rating the quality of evidence - inconsistency. Journal of Clinical Epidemiology2011;64(12):1294-302. [PMID: 21803546]">Guyatt 2011</a>; <a href="./references#CD003039-bbs2-0058" title="GuyattGH , OxmanAD , KunzR , WoodcockJ , BrozekJ , HelfandM , et al. GRADE guidelines: 8. Rating the quality of evidence - indirectness. Journal of Clinical Epidemiology2011;64(12):1303-10. [PMID: 21802903]">Guyatt 2011a</a>; <a href="./references#CD003039-bbs2-0059" title="GuyattG , OxmanAD , KunzR , BrozekJ , Alonso-CoelloP , RindD , et al. GRADE guidelines: 6. Rating the quality of evidence - imprecision. Journal of Clinical Epidemiology2011;64(12):1283-93. [PMID: 21839614]">Guyatt 2011b</a>; <a href="./references#CD003039-bbs2-0060" title="GuyattGH , OxmanAD , MontoriV , VistG , KunzR , BrozekJ , et al. GRADE guidelines: 5. Rating the quality of evidence - publication bias. Journal of Clinical Epidemiology2011;64(12):1277-82. [PMID: 21802904]">Guyatt 2011c</a>; <a href="./references#CD003039-bbs2-0061" title="GuyattGH , OxmanAD , VistG , KunzR , BrozekJ , Alonso-CoelloP , et al. GRADE guidelines: 4. Rating the quality of evidence - risk of bias. Journal of Clinical Epidemiology2011;64(4):407-15. [PMID: 21247734]">Guyatt 2011d</a>; <a href="./references#CD003039-bbs2-0062" title="GuyattG , OxmanAD , AklE , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [PMID: 21195583]">Guyatt 2011e</a>). </p> </section> <section id="CD003039-sec-0039"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We performed subgroup analyses on the following clinical characteristics:</p> <p> <ul id="CD003039-list-0010"> <li> <p>age group: use of CSF in children versus adults;</p> </li> <li> <p>type of CSF used;</p> </li> <li> <p>criteria for hospital discharge and</p> </li> <li> <p>type of tumor: mix versus hematological versus solid tumors.</p> </li> </ul> </p> </section> <section id="CD003039-sec-0040"> <h4 class="title">Sensitivity analysis</h4> <p>We assessed the robustness of our results by conducting a sensitivity analysis with respect to the methodological quality of the included RCTs. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003039-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003039-sec-0041"></div> <section id="CD003039-sec-0042"> <h3 class="title">Description of studies</h3> <p>Fourteen RCTs addressing the role of CSF in chemotherapy‐induced febrile neutropenia, involving a total of 1553 participants, were included in the final analysis. See '(<a href="./references#CD003039-sec-0098" title="">Characteristics of included studies</a>)' and '(<a href="./references#CD003039-sec-0099" title="">Characteristics of excluded studies</a>)' tables for details. No full economic evaluations were identified. </p> <section id="CD003039-sec-0043"> <h4 class="title">Randomization of participants versus episodes of febrile neutropenia</h4> <p>A particular difficulty with trials of febrile neutropenia is the problem of re‐randomization (<a href="./references#CD003039-bbs2-0073" title="PaesmansM . Statistical considerations in clinical trials testing empiric antibiotic regimens in patients with febrile neutropenia. Supportive Care in Cancer1998;6(5):438-43.">Paesmans 1998</a>). This practice has the potential to bias the results of clinical trials because of the possible dependence of outcomes on previous events. People who have already developed one episode of febrile neutropenia are expected to be more prone to develop another, which in turn may violate the assumption that all events must be independent of each other to allow proper analysis of a trial as well as the pooling of data in meta‐analysis (<a href="./references#CD003039-bbs2-0068" title="HozoI , DjulbegovicB , ClarkO , LymanGH , . Use of re-randomized data in meta-analysis. BMC Medical Research Methodology2005;10(5):17.">Hozo 2005a</a>). Five included trials (<a href="./references#CD003039-bbs2-0001" title="AnaissieEJ , VartivarianS , BodeyGP , LegrandC , KantarjianH , Abi-SaidD , et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. The American Journal of Medicine1996;100(1):17-23. ">Anaissie 1996</a>; <a href="./references#CD003039-bbs2-0006" title="Lopez-HernandezMA , Jimenez-AlvaradoR , Borbolla-EscobozaR , deDiego Flores-ChapaJ , Alvarado-IbarraM , Gonzalez-AvanteM , et al. Granulocyte colony-stimulating factor in the treatment of febrile neutropenia. Gaceta Médica de México2000;136(2):99-105. ">Lopez‐Hernandez 2000</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>; <a href="./references#CD003039-bbs2-0012" title="RodriguezZN , TordecillaCJ , CampbellBM , JoannonSP , RizzardiniLC , SotoAV , et al. Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia [Utilidad del factor estimulador de colonias de granulocitos (G-CSF) en episodios de neutropenia febril de alto riesgo en ninos con cancer.]. Revista Chilena de Infectologia2005;22(3):223-7. [PMID: 16077888]">Rodriguez 2005</a>) allowed people to be entered in the study and randomized more than once. These trials analysed 419 episodes of febrile neutropenia and are responsible for about one‐quarter of the total number of febrile neutropenia episodes and people included in this systematic review. It was impossible to extract data from these trials according to the number of people. As the practice of re‐randomization is allowed by the Immunocompromised Host Society (<a href="./references#CD003039-bbs2-0069" title="Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel. The Journal of Infectious Diseases1990;161(3):397-401.">IHS 1990</a>), we included these trials in our analyses. </p> </section> <section id="CD003039-sec-0044"> <h4 class="title">Results of the search</h4> <p>For this update we extended our search from the end of the search date in the original review to March 2014. We identified 1007 papers investigating G‐CSF or GM‐CSF in chemotherapy‐induced febrile neutropenia in our updated search of electronic databases. We did not identify any studies through other search methods. We selected and retrieved 12 articles for full‐text analysis. Of those identified, we excluded 11 for various reasons. We had excluded 21 studies in the original review process. Hence the total number of excluded studies from both reviews is 32 (<a href="./references#CD003039-sec-0099" title="">Characteristics of excluded studies</a>). Thus, in addition to the 13 studies included in the original review, we included 1 new study (<a href="./references#CD003039-bbs2-0012" title="RodriguezZN , TordecillaCJ , CampbellBM , JoannonSP , RizzardiniLC , SotoAV , et al. Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia [Utilidad del factor estimulador de colonias de granulocitos (G-CSF) en episodios de neutropenia febril de alto riesgo en ninos con cancer.]. Revista Chilena de Infectologia2005;22(3):223-7. [PMID: 16077888]">Rodriguez 2005</a>), bringing the included total to 14 (see <a href="#CD003039-fig-0001">Figure 1</a> for details). </p> <div class="figure" id="CD003039-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD003039-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD003039-sec-0045"> <h4 class="title">Included studies</h4> <p>Seven articles described the effects of G‐CSF (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>; <a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0006" title="Lopez-HernandezMA , Jimenez-AlvaradoR , Borbolla-EscobozaR , deDiego Flores-ChapaJ , Alvarado-IbarraM , Gonzalez-AvanteM , et al. Granulocyte colony-stimulating factor in the treatment of febrile neutropenia. Gaceta Médica de México2000;136(2):99-105. ">Lopez‐Hernandez 2000</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0012" title="RodriguezZN , TordecillaCJ , CampbellBM , JoannonSP , RizzardiniLC , SotoAV , et al. Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia [Utilidad del factor estimulador de colonias de granulocitos (G-CSF) en episodios de neutropenia febril de alto riesgo en ninos con cancer.]. Revista Chilena de Infectologia2005;22(3):223-7. [PMID: 16077888]">Rodriguez 2005</a><a href="./references#CD003039-bbs2-0014" title="YoshidaM , KarasawaM , NaruseT , FukudaM , HirashimaK , OhH , et al. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. International Journal of Hematology1999;69(2):81-8. ">Yoshida 1999</a>), six described the effects of GM‐CSF (<a href="./references#CD003039-bbs2-0001" title="AnaissieEJ , VartivarianS , BodeyGP , LegrandC , KantarjianH , Abi-SaidD , et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. The American Journal of Medicine1996;100(1):17-23. ">Anaissie 1996</a>; <a href="./references#CD003039-bbs2-0002" title="ArnbergH , LetochaH , NouF , WestlinJF , NilssonS . GM-CSF in chemotherapy-induced febrile neutropenia - a double-blind randomized study. Anticancer Research1998;18(2B):1255-60. ">Arnberg 1998</a>; <a href="./references#CD003039-bbs2-0004" title="BiesmaB , deVriesEG , WillemsePH , SluiterWJ , PostmusPE , LimburgPC , et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer1990;26(9):932-6. ">Biesma 1990</a>; <a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>; <a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>) and one was a three‐arm study in which participants were randomized to G‐CSF, GM‐CSF or placebo (<a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>). Six articles included people with an ANC less than 1 x 10<sup>9</sup>/L (<a href="./references#CD003039-bbs2-0001" title="AnaissieEJ , VartivarianS , BodeyGP , LegrandC , KantarjianH , Abi-SaidD , et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. The American Journal of Medicine1996;100(1):17-23. ">Anaissie 1996</a>; <a href="./references#CD003039-bbs2-0002" title="ArnbergH , LetochaH , NouF , WestlinJF , NilssonS . GM-CSF in chemotherapy-induced febrile neutropenia - a double-blind randomized study. Anticancer Research1998;18(2B):1255-60. ">Arnberg 1998</a>; <a href="./references#CD003039-bbs2-0004" title="BiesmaB , deVriesEG , WillemsePH , SluiterWJ , PostmusPE , LimburgPC , et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer1990;26(9):932-6. ">Biesma 1990</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>; <a href="./references#CD003039-bbs2-0014" title="YoshidaM , KarasawaM , NaruseT , FukudaM , HirashimaK , OhH , et al. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. International Journal of Hematology1999;69(2):81-8. ">Yoshida 1999</a>), six included people with an ANC less than 0.5 x 10<sup>9</sup>/L (<a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0006" title="Lopez-HernandezMA , Jimenez-AlvaradoR , Borbolla-EscobozaR , deDiego Flores-ChapaJ , Alvarado-IbarraM , Gonzalez-AvanteM , et al. Granulocyte colony-stimulating factor in the treatment of febrile neutropenia. Gaceta Médica de México2000;136(2):99-105. ">Lopez‐Hernandez 2000</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0012" title="RodriguezZN , TordecillaCJ , CampbellBM , JoannonSP , RizzardiniLC , SotoAV , et al. Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia [Utilidad del factor estimulador de colonias de granulocitos (G-CSF) en episodios de neutropenia febril de alto riesgo en ninos con cancer.]. Revista Chilena de Infectologia2005;22(3):223-7. [PMID: 16077888]">Rodriguez 2005</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>), one included those with an ANC less than 0.2 x 10<sup>9</sup>/L (<a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>) and one included participants with an ANC less than 0.1 x 10<sup>9</sup>/L (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>). Ten articles enrolled adults (<a href="./references#CD003039-bbs2-0001" title="AnaissieEJ , VartivarianS , BodeyGP , LegrandC , KantarjianH , Abi-SaidD , et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. The American Journal of Medicine1996;100(1):17-23. ">Anaissie 1996</a>; <a href="./references#CD003039-bbs2-0002" title="ArnbergH , LetochaH , NouF , WestlinJF , NilssonS . GM-CSF in chemotherapy-induced febrile neutropenia - a double-blind randomized study. Anticancer Research1998;18(2B):1255-60. ">Arnberg 1998</a>; <a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>; <a href="./references#CD003039-bbs2-0004" title="BiesmaB , deVriesEG , WillemsePH , SluiterWJ , PostmusPE , LimburgPC , et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer1990;26(9):932-6. ">Biesma 1990</a>; <a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>; <a href="./references#CD003039-bbs2-0014" title="YoshidaM , KarasawaM , NaruseT , FukudaM , HirashimaK , OhH , et al. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. International Journal of Hematology1999;69(2):81-8. ">Yoshida 1999</a>), three enrolled children (<a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>; <a href="./references#CD003039-bbs2-0012" title="RodriguezZN , TordecillaCJ , CampbellBM , JoannonSP , RizzardiniLC , SotoAV , et al. Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia [Utilidad del factor estimulador de colonias de granulocitos (G-CSF) en episodios de neutropenia febril de alto riesgo en ninos con cancer.]. Revista Chilena de Infectologia2005;22(3):223-7. [PMID: 16077888]">Rodriguez 2005</a>) and one included both (<a href="./references#CD003039-bbs2-0006" title="Lopez-HernandezMA , Jimenez-AlvaradoR , Borbolla-EscobozaR , deDiego Flores-ChapaJ , Alvarado-IbarraM , Gonzalez-AvanteM , et al. Granulocyte colony-stimulating factor in the treatment of febrile neutropenia. Gaceta Médica de México2000;136(2):99-105. ">Lopez‐Hernandez 2000</a>). Three articles enrolled participants with hematological malignancies only (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>; <a href="./references#CD003039-bbs2-0006" title="Lopez-HernandezMA , Jimenez-AlvaradoR , Borbolla-EscobozaR , deDiego Flores-ChapaJ , Alvarado-IbarraM , Gonzalez-AvanteM , et al. Granulocyte colony-stimulating factor in the treatment of febrile neutropenia. Gaceta Médica de México2000;136(2):99-105. ">Lopez‐Hernandez 2000</a>; <a href="./references#CD003039-bbs2-0014" title="YoshidaM , KarasawaM , NaruseT , FukudaM , HirashimaK , OhH , et al. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. International Journal of Hematology1999;69(2):81-8. ">Yoshida 1999</a>), one solid tumors only (<a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>) and ten articles included people with either type of malignancy (<a href="./references#CD003039-bbs2-0001" title="AnaissieEJ , VartivarianS , BodeyGP , LegrandC , KantarjianH , Abi-SaidD , et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. The American Journal of Medicine1996;100(1):17-23. ">Anaissie 1996</a>; <a href="./references#CD003039-bbs2-0002" title="ArnbergH , LetochaH , NouF , WestlinJF , NilssonS . GM-CSF in chemotherapy-induced febrile neutropenia - a double-blind randomized study. Anticancer Research1998;18(2B):1255-60. ">Arnberg 1998</a>; <a href="./references#CD003039-bbs2-0004" title="BiesmaB , deVriesEG , WillemsePH , SluiterWJ , PostmusPE , LimburgPC , et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer1990;26(9):932-6. ">Biesma 1990</a>; <a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>; <a href="./references#CD003039-bbs2-0012" title="RodriguezZN , TordecillaCJ , CampbellBM , JoannonSP , RizzardiniLC , SotoAV , et al. Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia [Utilidad del factor estimulador de colonias de granulocitos (G-CSF) en episodios de neutropenia febril de alto riesgo en ninos con cancer.]. Revista Chilena de Infectologia2005;22(3):223-7. [PMID: 16077888]">Rodriguez 2005</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>). </p> </section> <section id="CD003039-sec-0046"> <h4 class="title">Excluded studies</h4> <p>A total of 21 studies were excluded after full text review in the original version of this review. Eight of these 21 excluded studies were duplicate reports (<a href="./references#CD003039-bbs2-0017" title="BodeyGP , AnaissieE , GuttermanJ , Vadhan-RajS . Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection. European Journal of Clinical Microbiology &amp; Infectious Diseases1994;13 Suppl 2:S18-22. ">Bodey 1994</a>; <a href="./references#CD003039-bbs2-0020" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Filgrastim in the treatment of high-risk febrile neutropenia: results of a multicenter randomized phase III trial. Proceedings of the Annual Meeting of the American Society of Clinical Oncology1999;18:Abstract #2253. ">Garcia‐Carb 1999a</a>; <a href="./references#CD003039-bbs2-0021" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Randomized comparison of broad spectrum antibiotics with or without filgrastim in the treatment of patients with high-risk fever and grade IV neutropenia. European Journal of Cancer1999;35(Supplement 4):360. ">Garcia‐Carb 1999b</a>; <a href="./references#CD003039-bbs2-0028" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesMP , Lopez-BreaM , LópezE . Progress report of a randomized trial on the value of adding G-CSF or GM-CSF to standard antibiotic therapy in the treatment of febrile neutropenia. Annals of Oncology1992;3(Supplement 5: Growth factors / Oncogenes / Tumour suppressor):2. ">Mayordomo 1992</a>; <a href="./references#CD003039-bbs2-0029" title="MayordomoJI , RiveraF , Diaz PuenteMT , LianesMP , Lopez-BreaM , LopezE , et al. Decreasing morbidity and cost of treating febrile neutropenia by adding G-CSF and GM-CSF to standard antibiotic therapy: results of a randomized trial. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. Vol. 12. 1993:Abstract # 1510. ">Mayordomo 1993</a>; <a href="./references#CD003039-bbs2-0037" title="RavaudA , ChevreauC , BonichonF , MihuraJ , BuiBN , TabahI . A phase III trial of recombinant granulocyte-macrophage colony stimulating factor (GM-CSF) as corrective treatment in patients (pts) with neutropenic fever following antineoplastic chemotherapy (CT): results of an intermediate analysis. In: Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1995:Abstract A716. ">Ravaud 1995</a>; <a href="./references#CD003039-bbs2-0042" title="Uyl-de GrootCA , VellengaE , deVriesEG , LowenbergB , StoterGJ , RuttenFF . Treatment costs and quality of life with granulocyte-macrophage colony-stimulating factor in patients with antineoplastic therapy-related febrile neutropenia. Results of a randomised placebo-controlled trial. Pharmacoeconomics1997;12(3):351-60. ">Uyl‐de Groot 1997</a>; <a href="./references#CD003039-bbs2-0044" title="VellengaE , Uyl-De GrootC , StoterG , LowenbergB , De VriesE . Faster recovery of leukocytes due to haemopoietic growth factor in patients with chemotherapy-related granulocytopenia and fever, but no shortened hospital stay. Nederlands Tijdschrift voor Geneeskunde1996;140(32):1650-5. ">Vellenga 1996b</a>). In this update we excluded 11 studies after the full text review. The study by Montalar was published in abstract form only and no information on outcomes was available (<a href="./references#CD003039-bbs2-0031" title="MontalarJ , SantaballaA , OltraA , SeguraA , AparicioA , PastorM . Ofloxacin with or without stimulating colony-factors in the treatment of neutropenic fever. Annals of Oncology1998;9(Supplement 4 palliative and supportive care):151 abstract #724. ">Montalar 1998</a>). We tried to contact the authors of this abstract by e‐mail, but received no answer. Therefore, this trial was excluded from our analysis. We excluded the trial by (<a href="./references#CD003039-bbs2-0040" title="Timmer-BonteJN , deBooTM , SmitHJ , BiesmaB , WilschutFA , CheragwandiSA , et al. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch randomized phase III study. Journal of Clinical Oncology2005;23(31):7974-84. [PMID: 16258098]">Timmer‐Bonte 2005</a>) as it is a randomized trial addressing the prophylactic role of G‐CSF. </p> </section> </section> <section id="CD003039-sec-0047"> <h3 class="title">Risk of bias in included studies</h3> <p>Results of the 'Risk of bias' assessments are presented in (<a href="#CD003039-fig-0002">Figure 2</a>). The overall methodological quality of included studies for the majority of outcomes we judged to be low according to GRADE methodology (<a href="./full#CD003039-tbl-0001">summary of findings Table 1</a>). </p> <div class="figure" id="CD003039-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="original image" data-id="CD003039-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"></div> </div> <section id="CD003039-sec-0048"> <h4 class="title">Allocation</h4> <p>Three of the included studies described an adequate method of randomization (<a href="./references#CD003039-bbs2-0001" title="AnaissieEJ , VartivarianS , BodeyGP , LegrandC , KantarjianH , Abi-SaidD , et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. The American Journal of Medicine1996;100(1):17-23. ">Anaissie 1996</a>; <a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0006" title="Lopez-HernandezMA , Jimenez-AlvaradoR , Borbolla-EscobozaR , deDiego Flores-ChapaJ , Alvarado-IbarraM , Gonzalez-AvanteM , et al. Granulocyte colony-stimulating factor in the treatment of febrile neutropenia. Gaceta Médica de México2000;136(2):99-105. ">Lopez‐Hernandez 2000</a>) and five reported adequate concealment of the sequence of allocation (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>; <a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>). </p> </section> <section id="CD003039-sec-0049"> <h4 class="title">Blinding</h4> <p>Six trials were blinded (<a href="./references#CD003039-bbs2-0002" title="ArnbergH , LetochaH , NouF , WestlinJF , NilssonS . GM-CSF in chemotherapy-induced febrile neutropenia - a double-blind randomized study. Anticancer Research1998;18(2B):1255-60. ">Arnberg 1998</a>; <a href="./references#CD003039-bbs2-0004" title="BiesmaB , deVriesEG , WillemsePH , SluiterWJ , PostmusPE , LimburgPC , et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer1990;26(9):932-6. ">Biesma 1990</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>). Eight trials did not employ blinding in the conduct of the trial (<a href="./references#CD003039-bbs2-0001" title="AnaissieEJ , VartivarianS , BodeyGP , LegrandC , KantarjianH , Abi-SaidD , et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. The American Journal of Medicine1996;100(1):17-23. ">Anaissie 1996</a>; <a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>; <a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0006" title="Lopez-HernandezMA , Jimenez-AlvaradoR , Borbolla-EscobozaR , deDiego Flores-ChapaJ , Alvarado-IbarraM , Gonzalez-AvanteM , et al. Granulocyte colony-stimulating factor in the treatment of febrile neutropenia. Gaceta Médica de México2000;136(2):99-105. ">Lopez‐Hernandez 2000</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>; <a href="./references#CD003039-bbs2-0012" title="RodriguezZN , TordecillaCJ , CampbellBM , JoannonSP , RizzardiniLC , SotoAV , et al. Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia [Utilidad del factor estimulador de colonias de granulocitos (G-CSF) en episodios de neutropenia febril de alto riesgo en ninos con cancer.]. Revista Chilena de Infectologia2005;22(3):223-7. [PMID: 16077888]">Rodriguez 2005</a>; <a href="./references#CD003039-bbs2-0014" title="YoshidaM , KarasawaM , NaruseT , FukudaM , HirashimaK , OhH , et al. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. International Journal of Hematology1999;69(2):81-8. ">Yoshida 1999</a>). </p> </section> <section id="CD003039-sec-0050"> <h4 class="title">Incomplete outcome data</h4> <p>An ITT analysis was performed in ten trials (<a href="./references#CD003039-bbs2-0001" title="AnaissieEJ , VartivarianS , BodeyGP , LegrandC , KantarjianH , Abi-SaidD , et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. The American Journal of Medicine1996;100(1):17-23. ">Anaissie 1996</a>; <a href="./references#CD003039-bbs2-0002" title="ArnbergH , LetochaH , NouF , WestlinJF , NilssonS . GM-CSF in chemotherapy-induced febrile neutropenia - a double-blind randomized study. Anticancer Research1998;18(2B):1255-60. ">Arnberg 1998</a>; <a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>; <a href="./references#CD003039-bbs2-0014" title="YoshidaM , KarasawaM , NaruseT , FukudaM , HirashimaK , OhH , et al. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. International Journal of Hematology1999;69(2):81-8. ">Yoshida 1999</a>; <a href="./references#CD003039-bbs2-0012" title="RodriguezZN , TordecillaCJ , CampbellBM , JoannonSP , RizzardiniLC , SotoAV , et al. Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia [Utilidad del factor estimulador de colonias de granulocitos (G-CSF) en episodios de neutropenia febril de alto riesgo en ninos con cancer.]. Revista Chilena de Infectologia2005;22(3):223-7. [PMID: 16077888]">Rodriguez 2005</a>). </p> </section> <section id="CD003039-sec-0051"> <h4 class="title">Selective reporting</h4> <p>We did not have access to the trial protocols therefore we were unable to investigate the potential for selective reporting bias based only on trial publications. </p> </section> <section id="CD003039-sec-0052"> <h4 class="title">Other potential sources of bias</h4> <p>Seven trials were placebo controlled (<a href="./references#CD003039-bbs2-0002" title="ArnbergH , LetochaH , NouF , WestlinJF , NilssonS . GM-CSF in chemotherapy-induced febrile neutropenia - a double-blind randomized study. Anticancer Research1998;18(2B):1255-60. ">Arnberg 1998</a>; <a href="./references#CD003039-bbs2-0004" title="BiesmaB , deVriesEG , WillemsePH , SluiterWJ , PostmusPE , LimburgPC , et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer1990;26(9):932-6. ">Biesma 1990</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>). A sample size was preplanned in seven (<a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>; <a href="./references#CD003039-bbs2-0012" title="RodriguezZN , TordecillaCJ , CampbellBM , JoannonSP , RizzardiniLC , SotoAV , et al. Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia [Utilidad del factor estimulador de colonias de granulocitos (G-CSF) en episodios de neutropenia febril de alto riesgo en ninos con cancer.]. Revista Chilena de Infectologia2005;22(3):223-7. [PMID: 16077888]">Rodriguez 2005</a>), but the planned number was not reached in one trial (<a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>). </p> <p>Seven trials were multicentric studies (<a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>; <a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>; <a href="./references#CD003039-bbs2-0014" title="YoshidaM , KarasawaM , NaruseT , FukudaM , HirashimaK , OhH , et al. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. International Journal of Hematology1999;69(2):81-8. ">Yoshida 1999</a>). </p> <p>We noted that one of the studies reported a much higher rate of mortality in the control group than in the intervention group (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>). Because of this, and because of a lack of description of important baseline characteristics of the people in both groups, concerns regarding the comparability of the study arms in this trial (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>) have been raised in the literature (<a href="./references#CD003039-bbs2-0077" title="RubensteinEB . Colony stimulating factors in patients with fever and neutropenia. International Journal of Antimicrobial Agents2000;16(2):117-21.">Rubenstein 2000</a>). </p> </section> </section> <section id="CD003039-sec-0053"> <h3 class="title" id="CD003039-sec-0053">Effects of interventions</h3> <p>See: <a href="./full#CD003039-tbl-0001"><b>Summary of findings 1</b> Benefits and harms of CSF plus antibiotics versus antibiotics alone</a> </p> <p>Our analysis included 14 trials (15 comparisons) involving a total of 1553 participants, 797 of whom were randomized to the intervention group and 756 to the control group. Not all trials provided data on all endpoints. </p> <section id="CD003039-sec-0054"> <h4 class="title">Overall mortality</h4> <p>Data on overall mortality could be extracted from 13 trials (14 comparisons) with 1335 participants. The meta‐analysis showed a statistically non significant trend of a benefit favoring the intervention group (HR 0.74, 95% CI 0.47 to 1.16; P = 0.19) (<a href="./references#CD003039-fig-0003" title="">Analysis 1.1</a>). No heterogeneity was detected in the analysis (P = 0.53, I<sup>2</sup> = 0%). There were 35 deaths among 688 participants randomized to the intervention group and 45 among 647 randomized to the control group. However, it is important to note that 33% (15 of 45) of the events in the control group were reported in one study (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>). </p> </section> <section id="CD003039-sec-0055"> <h4 class="title">Infection‐related mortality</h4> <p>We could extract data on infection‐related mortality from 10 trials (11 comparisons) with 897 participants. The meta‐analysis showed a statistically non‐significant trend in favor of CSF use (HR 0.75, 95% CI 0.47 to 1.20; P = 0.23) (<a href="./references#CD003039-fig-0004" title="">Analysis 1.2</a>). No heterogeneity was detected (P = 0.33, I<sup>2</sup> = 12%). There were 15 infection‐related deaths among the 471 participants randomized to the intervention group and 25 among 426 randomized to the control group. However, it is important to note that 60% (15 of 25) of the events in the control group were reported in one study (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>). </p> </section> <section id="CD003039-sec-0056"> <h4 class="title">Participants hospitalized for more than 10 days</h4> <p>Data regarding the number of participants hospitalized for more than 10 days were extracted from eight trials (nine comparisons) that included 1221 participants. The pooled analysis showed a benefit in favor of the intervention group (RR 0.65, 95% CI 0.44 to 0.95; P = 0.03) (<a href="./references#CD003039-fig-0005" title="">Analysis 1.3</a>). Substantial heterogeneity was detected (P = 0.002, I<sup>2</sup> = 69%). </p> </section> <section id="CD003039-sec-0057"> <h4 class="title">Time to neutrophil recovery (number of participants with neutropenia (ANC &lt; 1000/mm<sup>3</sup>) for more than 5 to 10 days) </h4> <p>Data regarding the number of participants with neutropenia (ANC &lt; 1000/mm<sup>3</sup>) for more than 5 days were extracted from five trials (six comparisons) with a total of 794 participants. The pooled analysis revealed a significant effect of CSF plus antibiotics versus the antibiotics alone (RR 0.52, 95% CI 0.34 to 0.81; P = 0.004) for the outcome of time to neutrophil recovery (<a href="./references#CD003039-fig-0006" title="">Analysis 1.4</a>). There was substantial heterogeneity among these trials (P = 0.006, I<sup>2</sup> = 70%). </p> </section> <section id="CD003039-sec-0058"> <h4 class="title">Duration of grade IV neutropenia</h4> <p>Data were extracted from nine trials (10 comparisons), with a total of 1135 participants, for the outcome of duration of grade IV neutropenia. A significant effect of CSF plus antibiotics was detected compared with the control group (SMD = ‐1.70, 95% CI ‐2.65 to ‐0.76; P = 0.0004) (<a href="./references#CD003039-fig-0007" title="">Analysis 1.5</a>). There was considerable heterogeneity among these trials (P &lt; 0.00001, I<sup>2</sup> = 98%). </p> </section> <section id="CD003039-sec-0059"> <h4 class="title">Time to recovery from fever</h4> <p>Data were extracted from nine trials (10 comparisons), with a total of 966 participants, for the outcome of time to recovery from fever. A significant effect of CSF plus antibiotics was detected compared with the control group (SMD ‐0.49, 95% CI ‐0.90 to ‐0.09; P = 0.02) (<a href="./references#CD003039-fig-0008" title="">Analysis 1.6</a>). There was considerable heterogeneity among these trials (P &lt; 0.00001, I<sup>2</sup> = 89%). </p> </section> <section id="CD003039-sec-0060"> <h4 class="title">Time to withdrawal from antibiotics</h4> <p>Data were extracted from three trials, with a total of 457 participants, for the outcome of time to withdrawal from antibiotics. A significant effect of CSF plus antibiotics was detected compared with antibiotics alone (SMD ‐1.50, 95% CI ‐2.83 to ‐0.18; P = 0.03) (<a href="./references#CD003039-fig-0009" title="">Analysis 1.7</a>). There was considerable heterogeneity among these trials (P &lt; 0.00001, I<sup>2</sup> = 97%). </p> <section id="CD003039-sec-0061"> <h5 class="title">Treatment‐related harms</h5> <p>Treatment‐related harms were poorly reported in the included studies. We could only extract data related to DVT, and bone pain, joint pain and flu‐like symptoms from the included studies. Moreover, there was significant variation in the methods used by the authors to report treatment‐related harms. </p> </section> </section> <section id="CD003039-sec-0062"> <h4 class="title">Deep vein thrombosis</h4> <p>The number of participants developing DVT could be extracted from four studies with 389 participants. There were 9 cases of DVT among 194 participants randomized to the intervention group and 5 among 195 controls. The difference between the groups was not statistically significant (RR 1.68, 95% CI 0.72 to 3.93; P = 0.23) (<a href="./references#CD003039-fig-0010" title="">Analysis 1.8</a>). No heterogeneity was detected (P = 0.62, I<sup>2</sup> = 0%). </p> </section> <section id="CD003039-sec-0063"> <h4 class="title">Bone and joint pain, and flu‐like symptoms</h4> <p>Data on these outcomes could be extracted from six studies (seven comparisons) with 622 participants. Forty‐nine participants developed these symptoms from 328 participants randomized to the intervention group versus 25 of 294 randomized to the control group. The difference between the groups were statistically significant (RR 1.59, 95% CI 1.04 to 2.42; P = 0.03) indicating higher incidence of these events with use of CSF plus antibiotics compared with use of antibiotics alone (<a href="./references#CD003039-fig-0011" title="">Analysis 1.9</a>). No statistically significant heterogeneity was detected (P = 0.52, I<sup>2</sup> = 0%). </p> </section> <section id="CD003039-sec-0064"> <h4 class="title">Subgroup analyses</h4> <section id="CD003039-sec-0065"> <h5 class="title">Study population</h5> <p>Our results did not change based on the study population (adults only versus children versus mixed) for any of the outcomes (<a href="./references#CD003039-fig-0012" title="">Analysis 2.1</a>; <a href="./references#CD003039-fig-0014" title="">Analysis 2.3</a>; <a href="./references#CD003039-fig-0015" title="">Analysis 2.4</a>). We noticed a statistically significant subgroup differences between trials with adult population (RR 0.45 (95% CI 0.29 to 0.70); 4 RCTs; 608 participants) (<a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>) versus trial enrolling only children (RR 0.80 (95% CI 0.66 to 0.97); 1 RCT; 186 participants) (<a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>) for the outcome of time to neutrophil recovery with a stronger benefit for adults (test of interaction P = 0.02) (<a href="./references#CD003039-fig-0013" title="">Analysis 2.2</a>). However, both trials (enrolling adults and children) favored use of antibiotics and CSF compared with antibiotics alone, but a stronger effect was seen among adult population. </p> </section> <section id="CD003039-sec-0066"> <h5 class="title">Type of CSF</h5> <p>Our results did not change based on the type of CSF (G‐CSF and GM‐CSF) for any of the outcomes (<a href="./references#CD003039-fig-0016" title="">Analysis 3.1</a>; <a href="./references#CD003039-fig-0017" title="">Analysis 3.2</a>; <a href="./references#CD003039-fig-0019" title="">Analysis 3.4</a>; <a href="./references#CD003039-fig-0020" title="">Analysis 3.5</a>). We noticed a statistically significant subgroup differences between trials with G‐CSF (SMD ‐2.73 (95% CI ‐4.43 to ‐1.04); 5 RCTs; 784 participants) (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>; <a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>) versus trials with GM‐CSF (SMD ‐0.67 (95% CI ‐1.12 to ‐0.22); 5 RCTs; 351 participants) (<a href="./references#CD003039-bbs2-0004" title="BiesmaB , deVriesEG , WillemsePH , SluiterWJ , PostmusPE , LimburgPC , et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer1990;26(9):932-6. ">Biesma 1990</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>; <a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>) for the outcome of duration of grade IV neutropenia (ANC &lt; 500/mm<sup>3</sup>) with stronger benefit with G‐CSF (test of interaction P = 0.02) (<a href="./references#CD003039-fig-0018" title="">Analysis 3.3</a>). However, both CSF types (G‐CSF and GM‐CSF) plus antibiotics were statistically significantly superior to antibiotics alone for this outcome but a stronger effect was observed with G‐CSF use. </p> </section> <section id="CD003039-sec-0067"> <h5 class="title">Hospital discharge criteria</h5> <p>We also tested a possible impact of criteria for discharge from hospital on various outcomes. The criteria of discharge after 24 hours of resolution of fever was employed by one study (<a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>). Three studies used the criteria of discharge after 48 hours of resolution of fever (<a href="./references#CD003039-bbs2-0004" title="BiesmaB , deVriesEG , WillemsePH , SluiterWJ , PostmusPE , LimburgPC , et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer1990;26(9):932-6. ">Biesma 1990</a>; <a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>). Three studies used the criteria of discharge after 72 hours of resolution of fever (<a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>). One study used the criteria of discharge after 96 hours of resolution of fever (<a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>). The study by Rodriguez et al used criteria of discharge after at least 48 to 72 hours of resolution of fever (<a href="./references#CD003039-bbs2-0012" title="RodriguezZN , TordecillaCJ , CampbellBM , JoannonSP , RizzardiniLC , SotoAV , et al. Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia [Utilidad del factor estimulador de colonias de granulocitos (G-CSF) en episodios de neutropenia febril de alto riesgo en ninos con cancer.]. Revista Chilena de Infectologia2005;22(3):223-7. [PMID: 16077888]">Rodriguez 2005</a>). Four studies did not report the hospital discharge criteria (<a href="./references#CD003039-bbs2-0001" title="AnaissieEJ , VartivarianS , BodeyGP , LegrandC , KantarjianH , Abi-SaidD , et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. The American Journal of Medicine1996;100(1):17-23. ">Anaissie 1996</a>; <a href="./references#CD003039-bbs2-0002" title="ArnbergH , LetochaH , NouF , WestlinJF , NilssonS . GM-CSF in chemotherapy-induced febrile neutropenia - a double-blind randomized study. Anticancer Research1998;18(2B):1255-60. ">Arnberg 1998</a>; <a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>; <a href="./references#CD003039-bbs2-0006" title="Lopez-HernandezMA , Jimenez-AlvaradoR , Borbolla-EscobozaR , deDiego Flores-ChapaJ , Alvarado-IbarraM , Gonzalez-AvanteM , et al. Granulocyte colony-stimulating factor in the treatment of febrile neutropenia. Gaceta Médica de México2000;136(2):99-105. ">Lopez‐Hernandez 2000</a>). Different criteria required for hospital discharge (time since defervescence) had no effect on any endpoint (<a href="./references#CD003039-fig-0021" title="">Analysis 4.1</a>; <a href="./references#CD003039-fig-0023" title="">Analysis 4.3</a>; <a href="./references#CD003039-fig-0024" title="">Analysis 4.4</a>). We noticed a statistically significant subgroup differences between these trials based on hospital discharge criteria ((discharge after 24 hrs of resolution of fever: RR 0.54 (95% CI 0.35 to 0.84); 1 RCT; 68 participants); discharge after 48 hrs of resolution of fever: RR 0.14 (95% CI 0.04 to 0.48); 2 RCTs; 324 participants); discharge after 72 hrs of resolution of fever: RR 0.80 (95% CI 0.66 to 0.97); 1 RCT; 186 participants); discharge after 96 hrs of resolution of fever: RR 0.52 (95% CI 0.37 to 0.74); 1 RCT; 216 participants)] for the outcome of time to neutrophil recovery with the strongest benefit with discharge after 48 hours of resolution of fever (test of interaction P = 0.006) (<a href="./references#CD003039-fig-0022" title="">Analysis 4.2</a>). However, all these trials trials with varying hospital discharge criterions (discharge after 24, 48, 72, 96hours post fever resolution) favored use of antibiotics and CSF compared with antibiotics alone. </p> </section> <section id="CD003039-sec-0068"> <h5 class="title">Type of malignancy</h5> <p>The trials enrolling participants with mixed cancers (<a href="./references#CD003039-bbs2-0001" title="AnaissieEJ , VartivarianS , BodeyGP , LegrandC , KantarjianH , Abi-SaidD , et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. The American Journal of Medicine1996;100(1):17-23. ">Anaissie 1996</a>; <a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>) favored the use of CSF plus antibiotics (RR 0.64 (95% CI 0.45 to 0.89); 6 RCTs; 884 participants) compared with trial (<a href="./references#CD003039-bbs2-0014" title="YoshidaM , KarasawaM , NaruseT , FukudaM , HirashimaK , OhH , et al. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. International Journal of Hematology1999;69(2):81-8. ">Yoshida 1999</a>) enrolling participants with only hematological malignancies (RR 1.17 (95% CI 0.81 to 1.70); 1 RCT; 203 participants) (test of interaction P = 0.02) for the outcome of number of participants hospitalized for more than 10 days (<a href="./references#CD003039-fig-0025" title="">Analysis 5.1</a>). We noticed a statistically significant subgroup differences between trials based on type of malignancy [(mix tumors: SMD ‐1.50 (95% CI ‐2.50 to ‐0.50); 7 RCTs; 948 participants); (hematological malignancies: SMD ‐4.55 (95% CI ‐5.24 to ‐3.86); 1 RCT; 119 participants); (solid tumors: SMD ‐0.53 (95% CI ‐1.01 to ‐0.04); 1 RCT; 68 participants) for the outcome of duration of grade IV neutropenia (ANC &lt; 500/mm<sup>3</sup>) with stronger benefit for people with hematological malignancies (test of interaction P &lt; 0.00001) (<a href="./references#CD003039-fig-0027" title="">Analysis 5.3</a>). However, all of these trials enrolling participants with various different kinds of cancers (mix versus hematological malignancies versus solid tumors) favored use of antibiotics and CSF compared with antibiotics alone. Our results did not change based on the type of malignancy for any of the other outcomes with significant heterogeneity (<a href="./references#CD003039-fig-0026" title="">Analysis 5.2</a>; <a href="./references#CD003039-fig-0028" title="">Analysis 5.4</a>). </p> </section> </section> <section id="CD003039-sec-0069"> <h4 class="title">Sensitivity analyses</h4> <p>Our results did not change based on the methodological quality of studies for any outcomes. We have shown the analysis for the outcome of participants hospitalized for more than 10 days for allocation concealment (<a href="./references#CD003039-fig-0030" title="">Analysis 6.1</a>) and blinding (<a href="./references#CD003039-fig-0031" title="">Analysis 6.2</a>) for illustration purposes. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003039-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003039-sec-0070"></div> <section id="CD003039-sec-0071"> <h3 class="title" id="CD003039-sec-0071">Summary of main results</h3> <p>This systematic review summarized the totality of the evidence for the use of CSFs plus antibiotics in the treatment of chemotherapy‐induced febrile neutropenia among people with cancer. Overall and infection‐related mortality were not influenced by the addition of CSF to antibiotics. Participants treated with a CSF and antibiotics were less likely to be hospitalized for more than 10 days and had more participants with a faster neutrophil recovery than those treated with antibiotics alone. Similarly, people receiving CSF and antibiotics had shorter duration of neutropenia, more rapid recovery from fever and shorter duration of antibiotics use compared with people receiving antibiotics alone. The addition of CSF to antibiotics was well tolerated by participants: we found no significant difference in the incidence of DVT in individuals treated with CSF and antibiotics compared with those treated with antibiotics alone. However, we noticed a higher incidence of bone or joint pain, or flu‐like symptoms among participants receiving CSF and antibiotics compared with those receiving antibiotics alone. </p> <p>In our meta‐analysis, a CSF plus antibiotics was found to reduce the number of participants hospitalized for more than 10 days, a finding sustained in subgroup and sensitivity analyses. In particular, when meta‐analysis was restricted to trials with an adequate allocation concealment and to double‐blind trials, the two most powerful ways of avoiding bias, the result was unchanged (<a href="./references#CD003039-bbs2-0071" title="Mhaskar Rahul, Djulbegovic Benjamin, Magazin Anja, Soares HeloisaP , Kumar Ambuj. Published methodological quality of randomized controlled trials does not reflect the actual quality assessed in protocols. Journal of Clinical Epidemiology2012;65(6):602-9.">Mhaskar 2012</a>). The use of different criteria for hospital discharge also had no effect on this outcome. This benefit of CSF in shortening the duration of hospitalization has the potential to further influence current clinical practice. Shortening hospitalization translates into a reduction in costs, but this has to be weighed against the cost of CSF; hence, an cost effectiveness analysis should be performed in the light of this finding. A shorter duration in hospital may also translate into a better quality of life for the individual (<a href="./references#CD003039-bbs2-0080" title="SmeenkFW , vanHaastregtJC , deWitteLP , CrebolderHF . Effectiveness of home care programmes for patients with incurable cancer on their quality of life and time spent in hospital: systematic review. BMJ1998;316(7149):1939-44.">Smeenk 1998</a>); however, we did not perform a formal analysis of quality of life. </p> <p>A link between use of CSFs and an increase in the number of participants achieving neutrophil recovery was expected, but this is the first time that such an increase has been linked to clinical benefit, as defined by a shorter duration of hospitalization. Our findings show the benefit of using CSF in reducing the duration of fever and time to withdrawal from antibiotics. This has the potential to influence the decision about the use of CSFs, since the antibiotics used can be associated with substantial costs. Median time to antibiotic withdrawal was statistically significantly shorter in the intervention group than in the control group in all trials, representing a clinical benefit. Treatment‐related harms, such as bone and joint pain, flu‐like syndromes, were common and in some reports intense, but were not life‐threatening. </p> <p>In summary, this systematic review highlights the beneficial effect of a CSF added to antibiotics in terms of reducing the duration of hospitalization and expediting neutrophil recovery, compared with antibiotics alone, in participants diagnosed with chemotherapy‐induced febrile neutropenia. We think it would be highly desirable that individual patient data meta‐analyses is carried out in order to further explore the impact of CSF on overall and infection‐related mortality among this group of individuals. </p> <p>To augment the main clinical effectiveness systematic review we sought to identify economic evaluations, to support a Brief Economic Commentary, that have compared the use of a CSF plus antibiotics versus antibiotics alone for the treatment of individuals with established chemotherapy‐induced febrile neutropenia. Systematic supplemental searches were undertaken to identify evaluations relevant to this question. Results were screened using the review inclusion criteria, less study design, however, no full economic evaluations were identified. Several of the included RCTs identified economic benefits regarding a reduction in overall length of stay attributable to the use of CSF plus antibiotics, however they fell short of undertaking a full economic evaluation. </p> </section> <section id="CD003039-sec-0072"> <h3 class="title" id="CD003039-sec-0072">Overall completeness and applicability of evidence</h3> <p>Our analysis included 14 trials (15 comparisons) with a total of 1553 participants, 797 of whom were randomized to receive CSF plus antibiotics and 756 to antibiotics alone. For this update we conducted a comprehensive search of the literature without any language restrictions and we believe that there is low risk of potential publication bias and we found no evidence of this via the funnel plots. The conclusions we reach in this analysis have direct application to clinical practice for people diagnosed with chemotherapy‐induced febrile neutropenia. Our findings clearly demonstrate the superiority of supplementing antibiotics with a CSF compared with the use of antibiotics alone, with regard to reducing the duration of hospitalization and expediting neutrophil recovery. </p> </section> <section id="CD003039-sec-0073"> <h3 class="title" id="CD003039-sec-0073">Quality of the evidence</h3> <p>We assessed the quality of the included trials according to previously described quality domains (<a href="#CD003039-fig-0002">Figure 2</a>). The majority of included trials were not free of selection bias. Most included studies reported analyses according to the ITT principle, but some were not blinded and had high risks of performance and detection bias. Majority of the included trials were free of other biases. We considered the overall quality of evidence for a majority of the outcomes to be moderate to low across various outcomes according to the The Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria (<a href="./full#CD003039-tbl-0001">summary of findings Table 1</a>). The main reasons to downgrade the quality of evidence were inconsistency across the included studies and imprecision of results. </p> <p>We noted via a sub‐group analysis that participants diagnosed with hematological malignancies appeared to statistically non‐significantly benefit more from the addition of CSF to antibiotics than those with solid and mix tumors for the outcome of overall mortality (<a href="./references#CD003039-fig-0029" title="">Analysis 5.5</a>). However, this possible beneficial effect of CSF on mortality in people diagnosed with hematological malignancies was highly influenced by the results of one trial (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>). In this study, three times more participants died in the control group than in the intervention group (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>). This difference between groups is much higher than that seen in other, similar studies, and concerns regarding the comparability of the two groups investigated in this trial have been raised (<a href="./references#CD003039-bbs2-0077" title="RubensteinEB . Colony stimulating factors in patients with fever and neutropenia. International Journal of Antimicrobial Agents2000;16(2):117-21.">Rubenstein 2000</a>). Also in this trial by Aviles et al all deaths were considered to be due to infection (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>). Hence, we recommend caution in drawing a definitive conclusion about a possible beneficial effect of CSF on the outcome of overall mortality in individuals with hematological tumors. We noticed substantial heterogeneity for the outcome of number of participants hospitalized for more than 10 days. We explored the possible causes of heterogeneity to determine whether it was appropriate to pool the trials for this outcome. All trials but one trial (<a href="./references#CD003039-bbs2-0014" title="YoshidaM , KarasawaM , NaruseT , FukudaM , HirashimaK , OhH , et al. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. International Journal of Hematology1999;69(2):81-8. ">Yoshida 1999</a>) had a point estimate that favored the intervention group. This trial enrolled only people with hematological malignancies. We explored the impact of type of malignancy on number of participants hospitalized for more than 10 days (<a href="#CD003039-sec-0039">Subgroup analysis and investigation of heterogeneity</a>: type of malignancy). We also noticed that only two reached statistical significance (<a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>). By inspecting the forest plot, we could detect that trial by Mayordomo et al (<a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>) and Maher et al (<a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>) indicated a much stronger effect than that detected in all other trials. We therefore repeated our analysis, excluding these trials (<a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>). The exclusion resulted in a substantial reduction in the statistical heterogeneity (I<sup>2</sup> = 48%; P = 0.10) and the significance of the effect of CSF plus antibiotics on this outcome disappeared (RR 0.85, 95% CI = 0.61 to 1.17; P = 0.32). All but two studies (<a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>) favored the use of CSF plus antibiotics over the use of antibiotics alone, and the heterogeneity detected was mainly due to a superior effect of CSF plus antibiotics detected in these trials. Hence, our interpretation of these results is that CSF plus antibiotics significantly reduce the number of participants hospitalized for more than 10 days compared to the use of antibiotics alone, but that the magnitude of this effect cannot be precisely estimated using the currently available data. We also noticed considerable heterogeneity for the outcome of time to withdrawal from antibiotics. We noted that in all of the trials for this outcome the mean/median duration of ATB use was similar (mean of 5 days) among patients receiving CSF(<a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>). However, the high precision observed around the effect size in the trial by Garcio‐Carbonero et al (<a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>) compared with other two trial estimates was potentially leading to the substantial heterogeneity. The heterogeneity disappeared completely once we removed this trial from the analysis (P value = 0.72, I<sup>2</sup> = 0%) and the overall effect still showed benefit with the use of CSF plus ATB compared with ATB alone. </p> </section> <section id="CD003039-sec-0074"> <h3 class="title" id="CD003039-sec-0074">Potential biases in the review process</h3> <p>We did not find any methodological issues in the preparation of the review that could put it at risk for bias. </p> </section> <section id="CD003039-sec-0075"> <h3 class="title" id="CD003039-sec-0075">Agreements and disagreements with other studies or reviews</h3> <p>In 2002, Berghmans et al published a systematic review that addressed the question of the addition of CSF to antibiotics in the treatment of individuals with febrile neutropenia (<a href="./references#CD003039-bbs2-0047" title="BerghmansT , PaesmansM , LafitteJJ , MascauxC , MeertAP , JacquyC , et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Supportive Care in Cancer2002;10(3):181-8. [MEDLINE: 11904782]">Berghmans 2002</a>). This systematic review identified 11 trials and performed a meta‐analysis of mortality that included nine trials. The RR for mortality was 0.71 (95% CI 0.44 to 1.15). This result is similar to our findings. However, Berghmans et al failed to extract and include mortality data from two studies (<a href="./references#CD003039-bbs2-0004" title="BiesmaB , deVriesEG , WillemsePH , SluiterWJ , PostmusPE , LimburgPC , et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer1990;26(9):932-6. ">Biesma 1990</a>; <a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>). In addition, Berghmans et al used a very restricted search strategy (<a href="./references#CD003039-bbs2-0047" title="BerghmansT , PaesmansM , LafitteJJ , MascauxC , MeertAP , JacquyC , et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Supportive Care in Cancer2002;10(3):181-8. [MEDLINE: 11904782]">Berghmans 2002</a>): it included only articles in English, published up to 1998, and did not search relevant abstracts and conference proceedings. These restrictions related to the search methods may have led to the failure to include three studies satisfying the study inclusion criteria (<a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0006" title="Lopez-HernandezMA , Jimenez-AlvaradoR , Borbolla-EscobozaR , deDiego Flores-ChapaJ , Alvarado-IbarraM , Gonzalez-AvanteM , et al. Granulocyte colony-stimulating factor in the treatment of febrile neutropenia. Gaceta Médica de México2000;136(2):99-105. ">Lopez‐Hernandez 2000</a>; <a href="./references#CD003039-bbs2-0031" title="MontalarJ , SantaballaA , OltraA , SeguraA , AparicioA , PastorM . Ofloxacin with or without stimulating colony-factors in the treatment of neutropenic fever. Annals of Oncology1998;9(Supplement 4 palliative and supportive care):151 abstract #724. ">Montalar 1998</a>). Although the pooled results for mortality in Berghmans et al do not differ from ours, our analysis is broader (in that we included additional endpoints) and up‐to‐date (we included the trial by <a href="./references#CD003039-bbs2-0012" title="RodriguezZN , TordecillaCJ , CampbellBM , JoannonSP , RizzardiniLC , SotoAV , et al. Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia [Utilidad del factor estimulador de colonias de granulocitos (G-CSF) en episodios de neutropenia febril de alto riesgo en ninos con cancer.]. Revista Chilena de Infectologia2005;22(3):223-7. [PMID: 16077888]">Rodriguez 2005</a>) compared with the systematic review by Berghmans et al (<a href="./references#CD003039-bbs2-0047" title="BerghmansT , PaesmansM , LafitteJJ , MascauxC , MeertAP , JacquyC , et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Supportive Care in Cancer2002;10(3):181-8. [MEDLINE: 11904782]">Berghmans 2002</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003039-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD003039-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/full#CD003039-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-FIG-02" target="_blank"><b></b></a></p> </div><img alt="original image" data-id="CD003039-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/full#CD003039-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 1: Overall mortality" data-id="CD003039-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 1: Overall mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 2: Infection related mortality" data-id="CD003039-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 2: Infection related mortality </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 3: Patients with hospitalization for greater than10 days" data-id="CD003039-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 3: Patients with hospitalization for greater than10 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 4: Time to neutrophil recovery" data-id="CD003039-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 4: Time to neutrophil recovery </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 5: Duration of grade IV neutropenia" data-id="CD003039-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 5: Duration of grade IV neutropenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 6: Time to recovering from fever" data-id="CD003039-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 6: Time to recovering from fever </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 7: Time to withdrawal from antibiotics" data-id="CD003039-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 7: Time to withdrawal from antibiotics </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 8: Deep vein thrombosis" data-id="CD003039-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 8: Deep vein thrombosis </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 9: Bone and joint pain or flu‐like symptoms" data-id="CD003039-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Benefits and harms ‐ CSF + antibiotics vs antibiotics alone, Outcome 9: Bone and joint pain or flu‐like symptoms </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis ‐ Study population (children vs. adults), Outcome 1: Patients with hospitalization for greater than10 days" data-id="CD003039-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis ‐ Study population (children vs. adults), Outcome 1: Patients with hospitalization for greater than10 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis ‐ Study population (children vs. adults), Outcome 2: Time to neutrophil recovery" data-id="CD003039-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis ‐ Study population (children vs. adults), Outcome 2: Time to neutrophil recovery </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis ‐ Study population (children vs. adults), Outcome 3: Duration of grade IV neutropenia" data-id="CD003039-fig-0014" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis ‐ Study population (children vs. adults), Outcome 3: Duration of grade IV neutropenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis ‐ Study population (children vs. adults), Outcome 4: Time to recovering from fever" data-id="CD003039-fig-0015" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis ‐ Study population (children vs. adults), Outcome 4: Time to recovering from fever </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis ‐ Type of CSF (G‐CSF vs. GM‐CSF), Outcome 1: Patients with hospitalization for greater than 10 days" data-id="CD003039-fig-0016" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis ‐ Type of CSF (G‐CSF vs. GM‐CSF), Outcome 1: Patients with hospitalization for greater than 10 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis ‐ Type of CSF (G‐CSF vs. GM‐CSF), Outcome 2: Time to neutrophil recovery" data-id="CD003039-fig-0017" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis ‐ Type of CSF (G‐CSF vs. GM‐CSF), Outcome 2: Time to neutrophil recovery </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis ‐ Type of CSF (G‐CSF vs. GM‐CSF), Outcome 3: Duration of grade IV neutropenia" data-id="CD003039-fig-0018" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis ‐ Type of CSF (G‐CSF vs. GM‐CSF), Outcome 3: Duration of grade IV neutropenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis ‐ Type of CSF (G‐CSF vs. GM‐CSF), Outcome 4: Time to recovering from fever" data-id="CD003039-fig-0019" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis ‐ Type of CSF (G‐CSF vs. GM‐CSF), Outcome 4: Time to recovering from fever </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Subgroup analysis ‐ Type of CSF (G‐CSF vs. GM‐CSF), Outcome 5: Time to withdrawal from antibiotics" data-id="CD003039-fig-0020" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: Subgroup analysis ‐ Type of CSF (G‐CSF vs. GM‐CSF), Outcome 5: Time to withdrawal from antibiotics </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis ‐ Hospital discharge criteria (fever resolution), Outcome 1: Patients with hospitalization for greater than 10 days" data-id="CD003039-fig-0021" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis ‐ Hospital discharge criteria (fever resolution), Outcome 1: Patients with hospitalization for greater than 10 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis ‐ Hospital discharge criteria (fever resolution), Outcome 2: Time to neutrophil recovery" data-id="CD003039-fig-0022" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis ‐ Hospital discharge criteria (fever resolution), Outcome 2: Time to neutrophil recovery </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis ‐ Hospital discharge criteria (fever resolution), Outcome 3: Duration of grade IV neutropenia" data-id="CD003039-fig-0023" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis ‐ Hospital discharge criteria (fever resolution), Outcome 3: Duration of grade IV neutropenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Subgroup analysis ‐ Hospital discharge criteria (fever resolution), Outcome 4: Time to recovering from fever" data-id="CD003039-fig-0024" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Subgroup analysis ‐ Hospital discharge criteria (fever resolution), Outcome 4: Time to recovering from fever </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Subgroup analysis ‐ Type of malignancy, Outcome 1: Patients with hospitalisation for greater than10 days" data-id="CD003039-fig-0025" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Subgroup analysis ‐ Type of malignancy, Outcome 1: Patients with hospitalisation for greater than10 days </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Subgroup analysis ‐ Type of malignancy, Outcome 2: Time to neutrophil recovery" data-id="CD003039-fig-0026" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Subgroup analysis ‐ Type of malignancy, Outcome 2: Time to neutrophil recovery </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Subgroup analysis ‐ Type of malignancy, Outcome 3: Duration of grade IV neutropenia" data-id="CD003039-fig-0027" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Subgroup analysis ‐ Type of malignancy, Outcome 3: Duration of grade IV neutropenia </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-005.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Subgroup analysis ‐ Type of malignancy, Outcome 4: Time to recovering from fever" data-id="CD003039-fig-0028" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-005.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-005.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5: Subgroup analysis ‐ Type of malignancy, Outcome 4: Time to recovering from fever </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-005.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-005.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Subgroup analysis ‐ Type of malignancy, Outcome 5: Overall mortality" data-id="CD003039-fig-0029" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-005.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-005.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5: Subgroup analysis ‐ Type of malignancy, Outcome 5: Overall mortality</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-005.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Sensitivity analysis ‐ Patients hospitalized for more than 10 days by allocation concealment and blinding, Outcome 1: Adequacy of allocation concealment" data-id="CD003039-fig-0030" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Sensitivity analysis ‐ Patients hospitalized for more than 10 days by allocation concealment and blinding, Outcome 1: Adequacy of allocation concealment </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003039-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/urn:x-wiley:14651858:media:CD003039:CD003039-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Sensitivity analysis ‐ Patients hospitalized for more than 10 days by allocation concealment and blinding, Outcome 2: Blinding" data-id="CD003039-fig-0031" src="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_t/tCD003039-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Sensitivity analysis ‐ Patients hospitalized for more than 10 days by allocation concealment and blinding, Outcome 2: Blinding </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/media/CDSR/CD003039/image_n/nCD003039-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003039-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Benefits and harms of CSF plus antibiotics versus antibiotics alone</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>CSF plus ATB compared to ATB alone for chemotherapy induced febrile neutropenia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Population:</b> people with chemotherapy‐induced febrile neutropenia<br/><b>Settings:</b> in‐patient/hospital<br/><b>Intervention:</b> CSF plus ATB<br/><b>Comparison:</b> ATB alone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>No of Participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="3" scope="col" valign="top"> <p><b>Quality of the evidence<br/>(GRADE)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Assumed risk</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>ATB alone</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>CSF + ATB</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Overall mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>HR 0.74</b> <br/>(0.47 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1335<br/>(13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>70 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b><br/>(33 to 80) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b><br/>(14 to 34) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Infection‐related mortality</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.75</b> <br/>(0.47 to 1.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>897<br/>(10) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,2,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b><br/>(27 to 67) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>22 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b><br/>(10 to 26) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>People hospitalized for &gt; 10 days</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.65</b> <br/>(0.44 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1087<br/>(7) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>3,4</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>349 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>227 per 1000</b><br/>(153 to 331) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>338 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>220 per 1000</b><br/>(149 to 321) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Duration of grade IV neutropenia</b> (lower values signify better outcomes) </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>The mean duration of grade IV neutropenia in the intervention groups was<br/><b>1.70 standard deviations lower</b><br/>(2.65 to 0.76 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SMD ‐1.70</b> </p> <p>(‐2.65 to ‐0.76)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1135<br/>(9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>3,5</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to recovery from fever</b> </p> <p>(lower values signify better outcomes)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>The mean time to recovery from fever in the intervention groups was<br/><b>0.49 standard deviations lower</b><br/>(0.9 to 0.09 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SMD ‐0.49</b> </p> <p>(‐0.9 to ‐0.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>966<br/>(9) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>3,6</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to withdrawal from ATB</b> </p> <p>(lower values signify better outcomes)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p>The mean time to withdrawal from ATB in the intervention groups was<br/><b>1.5 standard deviations lower</b><br/>(2.83 to 0.18 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>SMD ‐1.5</b> </p> <p>(‐2.83 to ‐0.18)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>457<br/>(3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊝⊝<br/><b>low</b><sup>3,7</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Deep vein thrombosis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.68</b> <br/>(0.72 to 3.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>389<br/>(4) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/><b>low</b><sup>1,3</sup> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>26 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>43 per 1000</b><br/>(18 to 101) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>5 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>8 per 1000</b><br/>(4 to 20) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>ATB:</b> antibiotics; <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RR:</b> risk ratio; <b>SMD</b>: standardized mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>1</sup> Seven of the included articles described an adequate method of randomization (<a href="./references#CD003039-bbs2-0001" title="AnaissieEJ , VartivarianS , BodeyGP , LegrandC , KantarjianH , Abi-SaidD , et al. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived in cancer patients with fever and neutropenia. The American Journal of Medicine1996;100(1):17-23. ">Anaissie 1996</a>; <a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>; <a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0006" title="Lopez-HernandezMA , Jimenez-AlvaradoR , Borbolla-EscobozaR , deDiego Flores-ChapaJ , Alvarado-IbarraM , Gonzalez-AvanteM , et al. Granulocyte colony-stimulating factor in the treatment of febrile neutropenia. Gaceta Médica de México2000;136(2):99-105. ">Lopez‐Hernandez 2000</a>; <a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>; <a href="./references#CD003039-bbs2-0014" title="YoshidaM , KarasawaM , NaruseT , FukudaM , HirashimaK , OhH , et al. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. International Journal of Hematology1999;69(2):81-8. ">Yoshida 1999</a>) and five reported adequate concealment of the sequence of allocation (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>; <a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>). Seven trials were placebo controlled (<a href="./references#CD003039-bbs2-0002" title="ArnbergH , LetochaH , NouF , WestlinJF , NilssonS . GM-CSF in chemotherapy-induced febrile neutropenia - a double-blind randomized study. Anticancer Research1998;18(2B):1255-60. ">Arnberg 1998</a>; <a href="./references#CD003039-bbs2-0004" title="BiesmaB , deVriesEG , WillemsePH , SluiterWJ , PostmusPE , LimburgPC , et al. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. European Journal of Cancer1990;26(9):932-6. ">Biesma 1990</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0011" title="RiikonenP , SaarinenUM , MakipernaaA , HoviL , KomulainenA , PihkalaJ , JalankoH . Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: a double blind placebo-controlled study in children. Pediatric Infectious Disease Journal1994;13(3):197-202. ">Riikonen 1994</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>). A sample size was preplanned in seven (<a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>; <a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>; <a href="./references#CD003039-bbs2-0009" title="MitchellPL , MorlandB , StevensMC , DickG , EasleaD , MeyerLC , et al. Granulocyte colony-stimulating factor in established febrile neutropenia: a randomized study of pediatric patients. Journal of Clinical Oncology1997;15(3):1163-70. ">Mitchell 1997</a>; <a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>; <a href="./references#CD003039-bbs2-0013" title="VellengaE , Uyl-de GrootCA , deWitR , KeizerHJ , LowenbergB , ten HaaftMA , et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. Journal of Clinical Oncology1996;14(2):619-27. ">Vellenga 1996</a>; <a href="./references#CD003039-bbs2-0012" title="RodriguezZN , TordecillaCJ , CampbellBM , JoannonSP , RizzardiniLC , SotoAV , et al. Usefulness of G-CSF in pediatric high risk cancer patients with fever and neutropenia [Utilidad del factor estimulador de colonias de granulocitos (G-CSF) en episodios de neutropenia febril de alto riesgo en ninos con cancer.]. Revista Chilena de Infectologia2005;22(3):223-7. [PMID: 16077888]">Rodriguez 2005</a>), but the planned number was not reached in one trial (<a href="./references#CD003039-bbs2-0010" title="RavaudA , ChevreauC , CanyL , HouyauP , DohollouN , RocheH , et al. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. Journal of Clinical Oncology1998;16(9):2930-6. ">Ravaud 1998</a>). Hence we downgraded the quality of evidence by 1 for the risk of bias (also see footnote # 2 below).<br/><sup>2</sup> Of all the included trials only that by Aviles et al (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>) appeared to show a benefit of CSF plus antibiotics compared with antibiotics alone for the outcome of overall mortality. It is important to note that 33% (15 of 45) of the events for this outcome in the control group were reported in this trial. These 15 deaths represent 33% (15 of 45) of the total of deaths in the control group among all trials. Similarly, there were 15 infection‐related deaths among the 471 participants randomized to the intervention group and 25 among 426 randomized to the control group. However, it is important to note that 60% (15 of 25) of the events in the control group were reported in one study (<a href="./references#CD003039-bbs2-0003" title="AvilesA , GuzmanR , GarciaEL , TalaveraA , Diaz-MaqueoJC . Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulocytopenia. Anticancer Drugs1996;7(4):392-7. ">Aviles 1996</a>).<br/><sup>3</sup> A majority of the individual randomized controlled trials and the pooled estimates have wide CIs. We downgraded the quality of evidence by 1 for the observed imprecision. </p> <p><sup>4</sup> Substantial heterogeneity was detected (P = 0.0009, I<sup>2</sup> = 70%). As planned, we explored the possible causes of heterogeneity to determine if it was appropriate to pool the trials. All trials but one trial (<a href="./references#CD003039-bbs2-0014" title="YoshidaM , KarasawaM , NaruseT , FukudaM , HirashimaK , OhH , et al. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group. International Journal of Hematology1999;69(2):81-8. ">Yoshida 1999</a>) had a point estimate that favored the intervention group. This trial enrolled only people with hematological malignancies. We explored the impact of type of malignancy on number of participants hospitalized for more than 10 days (<a href="#CD003039-sec-0039">Subgroup analysis and investigation of heterogeneity</a>: type of malignancy). The trials enrolling people with mixed cancers favored the use of CSF plus antibiotics (RR 0.64, 95% CI 0.45 to 0.89) compared with trial enrolling people with only hematological malignancies (RR 1.17, 95% CI 0.81 to 1.70) (test of interaction P = 0.02) for the outcome of number of participants hospitalized for more than 10 days (<a href="./references#CD003039-fig-0025" title="">Analysis 5.1</a>). We also noticed that only two trials reached statistical significance (<a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>). By inspecting the forest plot, we could detect that trial by Mayordomo et al (<a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>) and Maher et al (<a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>) indicated a much stronger effect than that detected in all other trials. We therefore repeated our analysis, excluding these trials (<a href="./references#CD003039-bbs2-0007" title="MaherDW , LieschkeGJ , GreenM , BishopJ , Stuart-HarrisR , WolfM , et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Annals of Internal Medicine1994;121(7):492-501. ">Maher 1994</a>; <a href="./references#CD003039-bbs2-0008" title="MayordomoJI , RiveraF , Diaz-PuenteMT , LianesP , ColomerR , Lopez-BreaM , et al. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. Journal of the National Cancer Institute1995;87(11):803-8. ">Mayordomo 1995</a>). The exclusion resulted in a substantial reduction in the statistical heterogeneity (I<sup>2</sup> = 48%; P = 0.10) and the significance of the effect of CSF plus antibiotics on this outcome disappeared (RR 0.85, 95% CI = 0.61 to 1.17; P = 0.32). Hence we downgraded the quality of evidence by 1 for the observed inconsistency. </p> <p><sup>5</sup> Considerable heterogeneity was detected (P value &lt; 0.00001, I<sup>2</sup> = 98%). In a subgroup analysis according to CSF type, G‐CSF showed a statistically significantly stronger beneficial effect than GM‐CSF for the outcome of duration of grade IV neutropenia (<a href="./references#CD003039-fig-0018" title="">Analysis 3.3</a>). Nonetheless, we downgraded the quality of evidence by 1 for the observed inconsistency. </p> <p><sup>6</sup> Considerable heterogeneity was detected (P value &lt; 0.00001, I<sup>2</sup> = 89%). We downgraded the quality of evidence by 1 for the observed inconsistency. </p> <p><sup>7</sup> Considerable heterogeneity was detected (P value &lt; 0.00001, I<sup>2</sup> = 97%). We downgraded the quality of evidence by 1 for the observed inconsistency. We noted that in all of these trials the mean/median duration of ATB use was similar (mean of 5 days) among patients receiving CSF. However, the high precision observed around the effect size in the trial by Garcio‐Carbonero et al (<a href="./references#CD003039-bbs2-0005" title="Garcia-CarboneroR , MayordomoJI , TornamiraMV , Lopez-BreaM , RuedaA , GuillemV , et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. Journal of the National Cancer Institute2001;93(1):31-8. ">Garcia‐Carbonero 2001</a>) compared with other two trial estimates was potentially leading to the substantial heterogeneity. The heterogeneity disappeared completely once we removed this trial from the analysis (P value = 0.72, I<sup>2</sup> = 0%) and the overall effect still showed benefit with the use of CSF plus ATB compared with ATB alone. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Benefits and harms of CSF plus antibiotics versus antibiotics alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/full#CD003039-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003039-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Benefits and harms ‐ CSF + antibiotics vs antibiotics alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Overall mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.47, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Infection related mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>897</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.47, 1.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Patients with hospitalization for greater than10 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.44, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Time to neutrophil recovery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.34, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Duration of grade IV neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐2.65, ‐0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Time to recovering from fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐0.90, ‐0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Time to withdrawal from antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐2.83, ‐0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Deep vein thrombosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.72, 3.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Bone and joint pain or flu‐like symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [1.04, 2.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Benefits and harms ‐ CSF + antibiotics vs antibiotics alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003039-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis ‐ Study population (children vs. adults)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Patients with hospitalization for greater than10 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.44, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.41, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.24, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Time to neutrophil recovery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.34, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>608</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.29, 0.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.66, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Duration of grade IV neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐2.65, ‐0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>891</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.65 [‐2.75, ‐0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.93 [‐3.87, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Time to recovering from fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐0.90, ‐0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Adults</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.56 [‐1.15, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.46, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.3 Adults and Children</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.69 [‐1.33, ‐0.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis ‐ Study population (children vs. adults)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003039-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analysis ‐ Type of CSF (G‐CSF vs. GM‐CSF)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Patients with hospitalization for greater than 10 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.44, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.1 G‐CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>868</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.51, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1.2 GM‐CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.18, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Time to neutrophil recovery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.34, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 G‐CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>665</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.31, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 GM‐CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.04, 2.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Duration of grade IV neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐2.65, ‐0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.1 G‐CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.73 [‐4.43, ‐1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3.2 GM‐CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>351</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐1.12, ‐0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 Time to recovering from fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐0.90, ‐0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.1 G‐CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>621</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.78 [‐1.47, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4.2 GM‐CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>345</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.58, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Time to withdrawal from antibiotics <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐2.83, ‐0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.1 G‐CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.86 [‐3.80, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5.2 GM‐CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.77 [‐1.27, ‐0.28]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Subgroup analysis ‐ Type of CSF (G‐CSF vs. GM‐CSF)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003039-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup analysis ‐ Hospital discharge criteria (fever resolution)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Patients with hospitalization for greater than 10 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [0.32, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Discharge after 48h of resolution of fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.04, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Discharge after 72 hours of the resolution of fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>244</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.24, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.3 Discharge after 96 hours of the resolution of fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.39, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Time to neutrophil recovery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.34, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Discharge after 24h of resolution of fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.35, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Discharge after 48h of resolution of fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.04, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.3 Discharge after 72h of resolution of fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.66, 0.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.4 Discharge after 96h of resolution of fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.37, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Duration of grade IV neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1016</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.39 [‐2.29, ‐0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Discharge after 24 hours of resolution of fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐1.01, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Discharge after 48 hours of resolution of fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.87 [‐3.66, ‐0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.3 Discharge after 72 hours of resolution of fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.38 [‐3.04, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.4 Discharge after 96 hours of resolution of fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.44 [‐0.71, ‐0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 Time to recovering from fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>807</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐0.55, 0.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Discharge after 24 hours of resolution of fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.48, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Discharge after 48 hours of resolution of fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.72 [‐1.41, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.3 Discharge after 72 hours of resolution of fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.34, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.4 Discharge after 96 hours of resolution of fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.27, 0.27]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Subgroup analysis ‐ Hospital discharge criteria (fever resolution)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003039-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subgroup analysis ‐ Type of malignancy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Patients with hospitalisation for greater than10 days <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.44, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.1 Mix</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>884</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.39, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1.2 Hematological malignancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.81, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Time to neutrophil recovery <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>794</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [0.34, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Mix</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.26, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Solid tumors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.35, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Duration of grade IV neutropenia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐2.65, ‐0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.1 Mix</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>948</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.50 [‐2.50, ‐0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.2 Hematological malignancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.55 [‐5.24, ‐3.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3.3 Solid tumors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.53 [‐1.01, ‐0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.4 Time to recovering from fever <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>966</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.49 [‐0.90, ‐0.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.1 Mix</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>739</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.31 [‐0.62, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.2 Hematological malignancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.32 [‐2.53, ‐0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4.3 Solid tumors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.48, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.5 Overall mortality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1335</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.47, 1.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.1 Mix</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.60, 1.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.2 Hematological malignancies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>159</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.13, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5.3 Solid tumors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.00, 6.82]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Subgroup analysis ‐ Type of malignancy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003039-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sensitivity analysis ‐ Patients hospitalized for more than 10 days by allocation concealment and blinding</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Adequacy of allocation concealment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.44, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.1 Adequate allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>726</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.32, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1.2 Inadequate allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>361</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.41, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Blinding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1087</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.44, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Blinded studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>460</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.39, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Non‐Blinded studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>627</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.36, 1.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sensitivity analysis ‐ Patients hospitalized for more than 10 days by allocation concealment and blinding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003039.pub2/references#CD003039-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003039.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003039-note-0008">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003039-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD003039-note-0005">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD003039-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003039-note-0003">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003039-note-0004">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003039\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003039\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003039\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003039\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003039\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=fw9sVDQH&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003039.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003039.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003039.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003039.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003039.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725789903"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003039.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725789907"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003039.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e83d0ca4a936d',t:'MTc0MDcyNTc5MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 